_pmid,_doi,_publicationTitle,_year,_context,_confidence,_verdict,_usageType,targetAntigen
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,Anti-tyrosine hydroxylase (Rabbit polyclonal) EMD Millipore Cat#: AB152 RRID: AB_390204 IHC (1:1000),0.9,Accept,Experimental Usage,Anti-tyrosine hydroxylase (Rabbit polyclonal)
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,Anti-tyrosine hydroxylase (mouse monoclonal) ImmunoStar Cat#: 22941 RRID: AB_572268 IHC (1:1000),0.9,Accept,Experimental Usage,Anti-tyrosine hydroxylase (mouse monoclonal)
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,Anti-GFP (mouse polyclonal) Aves Cat#: GFP-1020 RRID: AB_10000240 IHC (1:1000),0.9,Accept,Experimental Usage,Anti-GFP (mouse polyclonal)
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"Immunoblotting was carried out using antibodies against neurofibromin (H12, Bethyl, iNF-07E)",0.9,Accept,Experimental Usage,neurofibromin antibody H12
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"antibodies against neurofibromin – Bethyl (Bethyl, Cat# A300-140A, primary 1:500, secondary 1:2000)",0.95,Accept,Experimental Usage,neurofibromin antibody Bethyl A300-140A
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"iNF-07E (gifted by iNFiXion Bioscience, Biointron, Cat# B21900201, primary 1:500, secondary 1:2000)",0.9,Accept,Experimental Usage,neurofibromin antibody iNF-07E
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"Immunoblotting was carried out using antibodies against...pERα S118 (Sigma, Cat# SAB450399)",0.85,Accept,Experimental Usage,pERα S118 antibody
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"Erα E115 (Abcam, Cat# 32063)",0.85,Accept,Experimental Usage,ERα E115 antibody
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"pERK T202/Y204 (Cell Signaling Technology, Cat#9101L)",0.85,Accept,Experimental Usage,pERK T202/Y204 antibody
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"ERK (Cell Signaling Technology, Cat#4695S)",0.85,Accept,Experimental Usage,ERK antibody
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"pAKT S473 (Cell Signaling Technology, Cat#9271L)",0.85,Accept,Experimental Usage,pAKT S473 antibody
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"AKT (Cell Signaling Technology, Cat#9272S)",0.85,Accept,Experimental Usage,AKT antibody
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"β-tubulin (Cell Signaling Technology, Cat#2146, primary 1:500, secondary 1:2000)",0.85,Accept,Experimental Usage,β-tubulin antibody
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"voltage-dependent anion channel (VDAC) (Invitrogen, Cat# PA1-954A, primary 1:1000, secondary 1:3000)",0.85,Accept,Experimental Usage,VDAC antibody
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"stained with anti-HLA-DR Percp-cy5.5 (eBioscience, 0.015 µg/test, San Diego, CA, USA), anti-CD33 APC (eBioscience, 0.125 µg/test)",0.9,Accept,Experimental Usage,"anti-HLA-DR Percp-cy5.5 (eBioscience, 0.015 µg/test, San Diego, CA, USA)"
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"stained with anti-HLA-DR Percp-cy5.5 (eBioscience, 0.015 µg/test, San Diego, CA, USA), anti-CD33 APC (eBioscience, 0.125 µg/test)",0.9,Accept,Experimental Usage,"anti-CD33 APC (eBioscience, 0.125 µg/test)"
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"anti-CD33 APC (eBioscience, 0.125 µg/test), and anti-CD11b FITC antibodies (eBioscience, 0.5 µg/test), along with corresponding isotype controls",0.9,Accept,Experimental Usage,"anti-CD11b FITC antibodies (eBioscience, 0.5 µg/test)"
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"incubated at 4 °C overnight with diluted (1:1000) primary antibodies against CD9 (Proteintech, 60232-1-Ig, Wuhan, China)",0.9,Accept,Experimental Usage,"CD9 (Proteintech, 60232-1-Ig, Wuhan, China)"
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"primary antibodies against CD9 (Proteintech, 60232-1-Ig, Wuhan, China), CD81 (Proteintech, 66866-1-Ig), TOMM20 (Proteintech, 11802-1-AP)",0.9,Accept,Experimental Usage,"CD81 (Proteintech, 66866-1-Ig)"
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"CD81 (Proteintech, 66866-1-Ig), TOMM20 (Proteintech, 11802-1-AP), HSP90 (Proteintech, 13171-1-AP)",0.9,Accept,Experimental Usage,"TOMM20 (Proteintech, 11802-1-AP)"
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"TOMM20 (Proteintech, 11802-1-AP), HSP90 (Proteintech, 13171-1-AP), AKT (CST, #9272S, Danvers, MA, USA)",0.9,Accept,Experimental Usage,"HSP90 (Proteintech, 13171-1-AP)"
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"HSP90 (Proteintech, 13171-1-AP), AKT (CST, #9272S, Danvers, MA, USA), p-AKT (CST, #4051S)",0.9,Accept,Experimental Usage,"AKT (CST, #9272S, Danvers, MA, USA)"
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"AKT (CST, #9272S, Danvers, MA, USA), p-AKT (CST, #4051S), ERK (CST, #4695)",0.9,Accept,Experimental Usage,"p-AKT (CST, #4051S)"
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"p-AKT (CST, #4051S), ERK (CST, #4695), p-ERK (CST, #9101S)",0.9,Accept,Experimental Usage,"ERK (CST, #4695)"
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"ERK (CST, #4695), p-ERK (CST, #9101S), following by incubation with appropriate HRP-conjugated secondary antibody",0.9,Accept,Experimental Usage,"p-ERK (CST, #9101S)"
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,"...Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies...",0.85,Accept,Experimental Usage,anti-total Erk1/2 antibody
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,"...Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies...",0.85,Accept,Experimental Usage,anti-phospho Erk1/2 antibody
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,"...Primary antibodies (Cell Signaling Technology) used for Western blotting were FLAG (rabbit, 14793)...",0.9,Accept,Experimental Usage,"FLAG antibody (rabbit, 14793)"
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,"...V5 (rabbit, 13202)...",0.9,Accept,Experimental Usage,"V5 antibody (rabbit, 13202)"
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,"...and HA (rabbit, 3724)...",0.9,Accept,Experimental Usage,"HA antibody (rabbit, 3724)"
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,...probed with a series of antibodies: pEGFR (Cell Signaling 3777)...,0.9,Accept,Experimental Usage,pEGFR antibody (Cell Signaling 3777)
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,...vinculin (Cell Signaling 19301)...,0.9,Accept,Experimental Usage,vinculin antibody (Cell Signaling 19301)
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,...HA-tag (Cell Signaling 2367)...,0.9,Accept,Experimental Usage,HA-tag antibody (Cell Signaling 2367)
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,...V5-tag (Cell Signaling 1320S)...,0.9,Accept,Experimental Usage,V5-tag antibody (Cell Signaling 1320S)
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,"...FLAG-tag (Sigma, F1804)...",0.9,Accept,Experimental Usage,"FLAG-tag antibody (Sigma, F1804)"
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,...KRAS (Sigma/Novus Biologicals WH0003845M1/H0003845M1)...,0.9,Accept,Experimental Usage,KRAS antibody (Sigma/Novus Biologicals WH0003845M1/H0003845M1)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,The primary antibodies and dilutions used were goat anti-collagen IV (Millipore AB769; 1:500),0.95,Accept,Experimental Usage,goat anti-collagen IV (Millipore AB769)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-MyHC type 1 (DSHB BA-D5; 1:500),0.95,Accept,Experimental Usage,mouse anti-MyHC type 1 (DSHB BA-D5)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-MyHC type 2A (DSHB SC-71; 1:200),0.95,Accept,Experimental Usage,mouse anti-MyHC type 2A (DSHB SC-71)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-laminin (Sigma-Aldrich L9393; 1:500),0.95,Accept,Experimental Usage,rabbit anti-laminin (Sigma-Aldrich L9393)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-Pax7 (DSHB Pax7; 1:10),0.95,Accept,Experimental Usage,mouse anti-Pax7 (DSHB Pax7)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-myosin heavy chain (Sigma-Aldrich 05-716; 1:1000),0.95,Accept,Experimental Usage,mouse anti-myosin heavy chain (Sigma-Aldrich 05-716)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,anti-beta III tubulin antibody (Sigma-Aldrich AB9354; 1:500),0.95,Accept,Experimental Usage,anti-beta III tubulin antibody (Sigma-Aldrich AB9354)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,anti-perilipin A/B antibody (Sigma-Aldrich p1873; 1:250),0.95,Accept,Experimental Usage,anti-perilipin A/B antibody (Sigma-Aldrich p1873)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,Antibodies used were rabbit anti-PPARG (Cell Signaling Technology 2443),0.95,Accept,Experimental Usage,rabbit anti-PPARG (Cell Signaling Technology 2443)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-phosphor (pThr172) AMPKa (Cell Signaling Technology 2535),0.95,Accept,Experimental Usage,rabbit anti-phosphor (pThr172) AMPKa (Cell Signaling Technology 2535)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-AMPKα (Cell Signaling Technology 2532),0.95,Accept,Experimental Usage,rabbit anti-AMPKα (Cell Signaling Technology 2532)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-β-actin (Cell Signaling Technology 58169),0.95,Accept,Experimental Usage,mouse anti-β-actin (Cell Signaling Technology 58169)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-β-tubulin (Sigma-Aldrich T8328),0.95,Accept,Experimental Usage,mouse anti-β-tubulin (Sigma-Aldrich T8328)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-phosphor (s235/236) S6 (Cell Signaling Technology 4858),0.95,Accept,Experimental Usage,rabbit anti-phosphor (s235/236) S6 (Cell Signaling Technology 4858)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-MyHC type 2B (DSHB BF-F3),0.95,Accept,Experimental Usage,mouse anti-MyHC type 2B (DSHB BF-F3)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"rabbit anti-phosphor (Ser473) AKT (Cell Signaling, #9271; 1:1000)",0.95,Accept,Experimental Usage,"rabbit anti-phosphor (Ser473) AKT (Cell Signaling, #9271)"
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"rabbit anti-phospho (Ser1101) IRS-1 (Cell Signaling, #2385; 1:1000)",0.95,Accept,Experimental Usage,"rabbit anti-phospho (Ser1101) IRS-1 (Cell Signaling, #2385)"
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"rabbit anti-phospho (Ser636/639) IRS-1 (Cell Signaling, #2388; 1:1000)",0.95,Accept,Experimental Usage,"rabbit anti-phospho (Ser636/639) IRS-1 (Cell Signaling, #2388)"
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"incubated with anti-DIG-Fab antibody coupled to alkaline phosphatase (Roche, 11093274910) in blocking solution",0.95,Accept,Experimental Usage,"anti-DIG-Fab antibody coupled to alkaline phosphatase (Roche, 11093274910)"
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"N-, K-, and H-RAS were detected with a 1:100 dilution of murine monoclonal pan-RAS antibody (BD Biosciences, San Diego, CA, USA, product #610002)",0.9,Accept,Experimental Usage,"pan-RAS antibody (BD Biosciences, product #610002)"
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"N-RAS was detected with a 1:400 dilution of a rabbit polyclonal N-RAS antibody (Santa Cruz, CA, USA, product #sc-519)",0.9,Accept,Experimental Usage,"N-RAS antibody (Santa Cruz, product #sc-519)"
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"RAB5A was detected with a 1:250 dilution of a rabbit polyclonal RAB5A antibody (Santa Cruz, Santa Cruz, CA, USA, product #sc-309)",0.9,Accept,Experimental Usage,"RAB5A antibody (Santa Cruz, product #sc-309)"
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"Non-prenylated RAP1A was detected with a 1:250 dilution of a goat polyclonal RAP1A antibody (Santa Cruz, product #1482)",0.9,Accept,Experimental Usage,"RAP1A antibody (Santa Cruz, product #1482)"
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"GAPDH was detected with a 1:1000 dilution of rabbit polyclonal antibody to GAPDH (Cell Signaling, Boston, MA, USA, product #2118)",0.85,Accept,Experimental Usage,"GAPDH antibody (Cell Signaling, product #2118)"
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"β-actin was detected with a 1:25,000 dilution of murine monoclonal antibody to β-actin (Sigma, St. Louis, MI, USA, product #A5441)",0.85,Accept,Experimental Usage,"β-actin antibody (Sigma, product #A5441)"
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,"cells were incubated with 2 µg/mL rabbit anti-human S100 antibody (DAKO, Glostrup, Denmark), 10 µg/mL secondary fluorescein isothiocyanate (FITC)-conjugated anti-rabbit antibody",0.9,Accept,Experimental Usage,"rabbit anti-human S100 antibody (DAKO, Glostrup, Denmark)"
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,"To stain fibroblasts, cells were incubated with 2 µg/mL anti-human CD90 antibody (Dianova, Hamburg, Germany), 2 µg/mL secondary FITC-conjugated goat anti-mouse IgG",0.9,Accept,Experimental Usage,"anti-human CD90 antibody (Dianova, Hamburg, Germany)"
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,"10 µg/mL secondary fluorescein isothiocyanate (FITC)-conjugated anti-rabbit antibody (DAKO). To stain fibroblasts, cells were incubated with",0.85,Accept,Experimental Usage,secondary fluorescein isothiocyanate (FITC)-conjugated anti-rabbit antibody (DAKO)
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,"2 µg/mL secondary FITC-conjugated goat anti-mouse IgG (DAKO). The nuclei were counterstained using 4',6-diamidino-2-phenylindole",0.85,Accept,Experimental Usage,secondary FITC-conjugated goat anti-mouse IgG (DAKO)
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,Schwann cells were incubated with antibody against s-100b (Sigma) as the primary overnight at 1:400 ratio,0.85,Accept,Experimental Usage,s-100b antibody (Sigma)
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,"treated with anti-rabbit IgG as secondary (Alexa Fluro 594, Invitrogen) for 2 hours at 1:1000 ratio",0.85,Accept,Experimental Usage,"anti-rabbit IgG (Alexa Fluro 594, Invitrogen)"
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",0.9,Accept,Experimental Usage,anti-Hmga2 antibody (Biocheck)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",0.85,Accept,Experimental Usage,anti-beta-Catenin antibody (BD bioscience)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",0.85,Accept,Experimental Usage,anti-Ck19 antibody (Abcam)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:1000 anti-Hmga2 (Biocheck); 1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences)",0.85,Accept,Experimental Usage,anti-Sox9 antibody (Millipore)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences); 1:1000 anti-Ck19 (Troma)",0.85,Accept,Experimental Usage,anti-Hsp90 antibody (BD Biosciences)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,1:1000 anti-Ck19 (Troma); 1:1000 anti-pErk (Cell Signaling),0.85,Accept,Experimental Usage,anti-pErk antibody (Cell Signaling)
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,"Mouse anti-Flag (Sigma-Aldrich) was used at 1∶20,000",0.95,Accept,Experimental Usage,Mouse anti-Flag (Sigma-Aldrich)
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,guinea-pig anti-Merlin [8] was used at 1∶5000,0.9,Accept,Experimental Usage,guinea-pig anti-Merlin
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,Secondary antibodies (Jackson ImmunoResearch) were diluted 1∶1000,0.8,Accept,Experimental Usage,Jackson ImmunoResearch
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,...followed by a 12-min incubation with the CONFIRM anti-Ki67 (clone 30-9) rabbit monoclonal primary antibody (Roche) and detection with the UltraView Universal DAB detection kit...,0.95,Accept,Experimental Usage,CONFIRM anti-Ki67 (clone 30-9) rabbit monoclonal primary antibody (Roche)
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,"...followed by an incubation with polyclonal anti-collagen XV (Sigma-Aldrich, HPA017913, 1:1000) or in-house monoclonal anti-collagen XVIII...",0.95,Accept,Experimental Usage,"polyclonal anti-collagen XV (Sigma-Aldrich, HPA017913)"
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,"...or in-house monoclonal anti-collagen XVIII (ref. [ 46 ], DB144-N2, 7 µg/ml) primary antibody...",0.9,Accept,Experimental Usage,monoclonal anti-collagen XVIII (DB144-N2)
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,"...stained with monoclonal anti-human MIA antibody (R&D Systems, McKinley Place NE, Minneapolis) diluted at 1:40...",0.9,Accept,Experimental Usage,monoclonal anti-human MIA antibody (R&D Systems)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"Immunofluorescence staining was performed using the following primary antibodies: GFAP (Sigma; St. Louis, MO)",0.9,Accept,Experimental Usage,GFAP antibody (Sigma)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.9,Accept,Experimental Usage,AQP4 antibody (Chemicon)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.9,Accept,Experimental Usage,NG2 antibody (Chemicon)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.9,Accept,Experimental Usage,O4 antibody (Chemicon)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.9,Accept,Experimental Usage,LHX2 antibody (Chemicon)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"APC (Calbiochem; San Diego, CA)",0.9,Accept,Experimental Usage,APC antibody (Calbiochem)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)",0.9,Accept,Experimental Usage,FOXG1 antibody (Abcam)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)",0.9,Accept,Experimental Usage,FOXP2 antibody (Abcam)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"HOXB3 (Santa Cruz Biotechnology; Santa Cruz, CA)",0.9,Accept,Experimental Usage,HOXB3 antibody (Santa Cruz)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,GLAST (a gift from Dr. Watanabe; ( Shibata et al. 1997 )),0.85,Accept,Experimental Usage,GLAST antibody
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"Immunohistochemical staining was performed using GFAP (Zymed, San Francisco, CA) or Ki-67 (BD Pharmingen, San Diego, CA) antibodies",0.9,Accept,Experimental Usage,Ki-67 antibody (BD Pharmingen)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"Rabbit anti-NF1GRP-D (Santa Cruz Biotechnology, Santa Cruz, CA) was used at a 1:200 dilution to detect neurofibromin expression",0.9,Accept,Experimental Usage,NF1GRP-D antibody (Santa Cruz)
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"α-tubulin (Sigma, St. Louis, MO) was employed for normalization",0.9,Accept,Experimental Usage,α-tubulin antibody (Sigma)
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,Anti-Merlin monoclonal antibody 4B5 was made by W. Ip,0.9,Accept,Experimental Usage,Anti-Merlin monoclonal antibody 4B5
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,Horseradish peroxidase (HRP) conjugated an antibody specific for GFP (cat. no. 600–103-215) was from Rockland,0.85,Accept,Experimental Usage,GFP antibody (cat. no. 600–103-215)
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,specific for RFP (cat no. ab34767) was from Abcam,0.85,Accept,Experimental Usage,RFP antibody (cat no. ab34767)
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,Antibody specific for YAP1 was from Cell Signaling Inc.,0.8,Accept,Experimental Usage,YAP1 antibody
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",0.85,Accept,Experimental Usage,rabbit anti-HA antibody
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",0.85,Accept,Experimental Usage,mouse anti-HA antibody
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",0.85,Accept,Experimental Usage,9B11 mouse anti-myc antibody
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc), Invitrogen (mouse anti-V5)",0.85,Accept,Experimental Usage,mouse anti-V5 antibody
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG)",0.85,Accept,Experimental Usage,mouse anti-FLAG antibody
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG)",0.85,Accept,Experimental Usage,rabbit anti-FLAG antibody
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",0.95,Accept,Experimental Usage,Phosphorylated ERK Thr202/Tyr204 (catalog #4376)
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",0.95,Accept,Experimental Usage,phosphorylated Akt Ser473 (#9271)
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",0.95,Accept,Experimental Usage,phosphorylated S6 Ser235/236 (#2211)
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Coverslips were permeabilized and probed with anti- γH2AX Ser139 antibody (Millipore), followed by anti-rabbit AlexaFluor 488 secondary antibody",0.9,Accept,Experimental Usage,anti-γH2AX Ser139 antibody (Millipore)
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"probed with anti- γH2AX Ser139 antibody (Millipore), followed by anti-rabbit AlexaFluor 488 secondary antibody (Molecular Probes).",0.9,Accept,Experimental Usage,anti-rabbit AlexaFluor 488 secondary antibody (Molecular Probes)
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"Primary antibodies were obtained from the following sources: HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc.)",0.85,Accept,Experimental Usage,HIF-1α antibody
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"BNIP3 (Sigma, St. Louis, MO); Lamin A/C (BD Transduction Laboratories, Franklin Lakes, NJ)",0.85,Accept,Experimental Usage,BNIP3 antibody
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"Primary antibodies were obtained from the following sources: HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1",0.85,Accept,Experimental Usage,BECLIN1 antibody
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"GAPDH, BCL-2 and PUMA (Cell Signaling, Danvers, MA); LC3 (Abgent, San Diego, CA)",0.85,Accept,Experimental Usage,LC3 antibody
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-p53 (NCL-p53-CM5p, 1:1000, Leica Biosystems)",0.9,Accept,Experimental Usage,"rabbit anti-p53 (NCL-p53-CM5p, 1:1000, Leica Biosystems)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"mouse anti-Ki67 (550609, 1:500, BD Pharmingen)",0.9,Accept,Experimental Usage,"mouse anti-Ki67 (550609, 1:500, BD Pharmingen)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-Olig2 (AB9610, 1:2000, EMD Millipore)",0.9,Accept,Experimental Usage,"rabbit anti-Olig2 (AB9610, 1:2000, EMD Millipore)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"mouse anti-GFAP (556330, 1:2000, BD Pharmingen)",0.9,Accept,Experimental Usage,"mouse anti-GFAP (556330, 1:2000, BD Pharmingen)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-Pten (9559S, 1:1000, Cell Signaling)",0.9,Accept,Experimental Usage,"rabbit anti-Pten (9559S, 1:1000, Cell Signaling)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-p-S6 (5364S, 1:2000, Cell Signaling)",0.9,Accept,Experimental Usage,"rabbit anti-p-S6 (5364S, 1:2000, Cell Signaling)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rat anti-BrdU (ab6326, 1:500, Abcam)",0.9,Accept,Experimental Usage,"rat anti-BrdU (ab6326, 1:500, Abcam)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-p-Erk (9101S, 1:2000, Cell Signaling)",0.9,Accept,Experimental Usage,"rabbit anti-p-Erk (9101S, 1:2000, Cell Signaling)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"mouse anti-Ascl1 (556604, 1:100-1:200, BD PharMingen)",0.9,Accept,Experimental Usage,"mouse anti-Ascl1 (556604, 1:100-1:200, BD PharMingen)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-Ezh2 (5246S, 1:1000–1:2000, Cell Signaling)",0.9,Accept,Experimental Usage,"rabbit anti-Ezh2 (5246S, 1:1000–1:2000, Cell Signaling)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-BLBP (ab32423, 1:200, Abcam)",0.9,Accept,Experimental Usage,"rabbit anti-BLBP (ab32423, 1:200, Abcam)"
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-Nf1 (SC-67, 1:1000, Santa Cruz Biotechnology)",0.9,Accept,Experimental Usage,"rabbit anti-Nf1 (SC-67, 1:1000, Santa Cruz Biotechnology)"
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution,0.9,Accept,Experimental Usage,ABCC1 antibody (Abcam ab24102)
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution,0.9,Accept,Experimental Usage,S100 antibody (Dako Z0311)
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"Primary antibodies used in western blot analysis were: mouse anti-β-actin, mouse anti-α-tubulin, and mouse anti-α-smooth muscle actin (α-SMA), all from Sigma-Aldrich",0.85,Accept,Experimental Usage,mouse anti-β-actin
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"Primary antibodies used in western blot analysis were: mouse anti-β-actin, mouse anti-α-tubulin, and mouse anti-α-smooth muscle actin (α-SMA), all from Sigma-Aldrich",0.85,Accept,Experimental Usage,mouse anti-α-tubulin
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"Primary antibodies used in western blot analysis were: mouse anti-β-actin, mouse anti-α-tubulin, and mouse anti-α-smooth muscle actin (α-SMA), all from Sigma-Aldrich",0.85,Accept,Experimental Usage,mouse anti-α-smooth muscle actin (α-SMA)
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"rabbit anti-GAPDH, rabbit anti-Histone 3, rabbit anti-Merlin, mouse anti-p53, mouse anti-Ki67, and rabbit anti-β-catenin, all from Cell Signaling",0.95,Accept,Experimental Usage,rabbit anti-Merlin
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"goat polyclonal anti-CTGF and mouse anti-NHE1 (clone 54), anti-Poly-ADP Ribose Polymerase (PARP), anti-cleaved PARP (Asp214) and anti-pSer807/811-Rb, all from Santa Cruz Biotechnology",0.85,Accept,Experimental Usage,goat polyclonal anti-CTGF
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"goat polyclonal anti-CTGF and mouse anti-NHE1 (clone 54), anti-Poly-ADP Ribose Polymerase (PARP), anti-cleaved PARP (Asp214) and anti-pSer807/811-Rb, all from Santa Cruz Biotechnology",0.9,Accept,Experimental Usage,mouse anti-NHE1 (clone 54)
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,MM-121 (generously provided by Merrimack Pharmaceuticals). Drug treatment concentrations and times are described,0.85,Accept,Experimental Usage,MM-121
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,Rabbit anti-NF1 antibody (A300-140A) was purchased from Bethyl Laboratories,0.95,Accept,Experimental Usage,A300-140A
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"The rabbit anti-phospho-ERK1/2 (p44/42 MAPK) (Thr202/Tyr204) antibody (#9101), anti-ERK1/2 (p44/42 MAPK) antibody (#9102) and rabbit anti-GFP antibody (#2555) were purchased from Cell Signaling Technologies",0.95,Accept,Experimental Usage,#9101
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"The rabbit anti-phospho-ERK1/2 (p44/42 MAPK) (Thr202/Tyr204) antibody (#9101), anti-ERK1/2 (p44/42 MAPK) antibody (#9102) and rabbit anti-GFP antibody (#2555) were purchased from Cell Signaling Technologies",0.95,Accept,Experimental Usage,#9102
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"The rabbit anti-phospho-ERK1/2 (p44/42 MAPK) (Thr202/Tyr204) antibody (#9101), anti-ERK1/2 (p44/42 MAPK) antibody (#9102) and rabbit anti-GFP antibody (#2555) were purchased from Cell Signaling Technologies",0.95,Accept,Experimental Usage,#2555
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"Goat anti-GFP antibody (600-101-215) was purchased from Rockland Immunochemicals, Inc.",0.95,Accept,Experimental Usage,600-101-215
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,mouse anti-NGFR (p75) antibody (AB-N07) was purchased from Advanced Targeting System,0.95,Accept,Experimental Usage,AB-N07
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,rabbit anti-S100B antibody (Z0311) was purchased from DAKO,0.95,Accept,Experimental Usage,Z0311
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"The anti-βActin (C-11, SC-1615HRP) HRP antibody was purchased from Santa Cruz Biotechnology",0.95,Accept,Experimental Usage,SC-1615HRP
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,mouse anti-HA antibody (26183) was purchased from Invitrogen,0.95,Accept,Experimental Usage,26183
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,Human Nuclear Antigen (HNA) recombinant rabbit Monoclonal Antibody (235-1 R) was purchased from ThermoFisher,0.95,Accept,Experimental Usage,235-1 R
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",0.85,Accept,Experimental Usage,rabbit primary antibodies for p44/42 MAPK (ERK1/2)
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K)",0.85,Accept,Experimental Usage,rabbit primary antibodies for p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2)
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K)",0.85,Accept,Experimental Usage,rabbit primary antibodies for phosphatidylinositol 3-kinase (PI3K)
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs (Whitby, Ontario, Canada).",0.8,Accept,Experimental Usage,anti-rabbit conjugated secondary antibody
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,"S100 (1:400, Dako, Glostrun Denman, Carpinteria, CA) was visualized using fluorescent immunohistochemistry",0.85,Accept,Experimental Usage,S100 antibody
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"The slides were incubated in their prospective antibodies for 30 min: indoleamine 2,3-dioxygenase rabbit monoclonal (1:100, Abcam, Cambridge, UK)",0.9,Accept,Experimental Usage,"indoleamine 2,3-dioxygenase rabbit monoclonal (1:100, Abcam, Cambridge, UK)"
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"AHR antibody mouse monoclonal (1:50, Santa Cruz, Dallas, TX, USA)",0.9,Accept,Experimental Usage,"AHR antibody mouse monoclonal (1:50, Santa Cruz, Dallas, TX, USA)"
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"antibody-TDO2, rabbit/IgG polyclonal (1:100, Proteintech, Rosemont, IL, USA)",0.9,Accept,Experimental Usage,"antibody-TDO2, rabbit/IgG polyclonal (1:100, Proteintech, Rosemont, IL, USA)"
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage,Merlin antibody (1:1000) from Cell Signaling Technology
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage,pMerlin antibody (1:500) from Cell Signaling Technology
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",0.85,Accept,Experimental Usage,HDAC1 antibody (1:1000) from Cell Signaling Technology
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage,PDLIM2 antibody (1:500) from Cell Signaling Technology
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore,0.9,Accept,Experimental Usage,PDLIM2 antibody (1:500) from Santa Cruz Biotechnology
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore,0.85,Accept,Experimental Usage,GAPDH antibody (1:50.000) from Millipore
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",0.85,Accept,Experimental Usage,EMA antibody
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",0.85,Accept,Experimental Usage,vimentin antibody
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",0.85,Accept,Experimental Usage,MIB-1 antibody
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam)",0.95,Accept,Experimental Usage,"CD31 antibody (ab28364, Abcam)"
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam)",0.95,Accept,Experimental Usage,"AXL antibody (ab227871, Abcam)"
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)",0.95,Accept,Experimental Usage,"pAXL antibody (Cat#5724, Cell Signaling Technology)"
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology)",0.95,Accept,Experimental Usage,"pAKT antibody (Cat #9271, Cell Signaling Technology)"
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-CalbindinD-28K (rabbit polyclonal, 1:2000 Swant CB-38a, Marly, Switzerland and mouse monoclonal 1:1000 Sigma-Aldrich (clone CB-955))",0.9,Accept,Experimental Usage,"anti-CalbindinD-28K (rabbit polyclonal, 1:2000 Swant CB-38a)"
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-CalbindinD-28K (rabbit polyclonal, 1:2000 Swant CB-38a, Marly, Switzerland and mouse monoclonal 1:1000 Sigma-Aldrich (clone CB-955))",0.9,Accept,Experimental Usage,anti-CalbindinD-28K (mouse monoclonal 1:1000 Sigma-Aldrich clone CB-955)
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-Merlin (rabbit polyclonal antibody, A-19 (sc-331) and C-18 (sc-332), 1:50; Santa Cruz, Heidelberg, Germany)",0.95,Accept,Experimental Usage,"anti-Merlin (rabbit polyclonal antibody, A-19 (sc-331))"
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-Merlin (rabbit polyclonal antibody, A-19 (sc-331) and C-18 (sc-332), 1:50; Santa Cruz, Heidelberg, Germany)",0.95,Accept,Experimental Usage,"anti-Merlin (rabbit polyclonal antibody, C-18 (sc-332))"
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-Olig2 (mouse monoclonal antibody, 1:500; Millipore (AB9610), Darmstadt, Germany)",0.9,Accept,Experimental Usage,"anti-Olig2 (mouse monoclonal antibody, 1:500; Millipore AB9610)"
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-MBP (mouse monoclonal antibody, 1:500; Chemikon (MAB384), Schwalbach, Germany)",0.9,Accept,Experimental Usage,"anti-MBP (mouse monoclonal antibody, 1:500; Chemikon MAB384)"
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-Merlin (clone A-19 and C-18, 1:50, Santa Cruz Biotechnology, Heidelberg, Germany; or HPA003097, 1:100, Atlas Antibodies, Bromma, Sweden)",0.9,Accept,Experimental Usage,"anti-Merlin (HPA003097, 1:100, Atlas Antibodies)"
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-GFP (A11122, 1:500, Thermo Fisher, Schwerte, Germany)",0.9,Accept,Experimental Usage,"anti-GFP (A11122, 1:500, Thermo Fisher)"
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti Ki67 (15580, 1:500, Abcam, Cambridge, UK)",0.9,Accept,Experimental Usage,"anti Ki67 (15580, 1:500, Abcam)"
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti phospho-Histone H3 (pH3-Ser10, 06–570, 1:1000, Millipore, Darmstadt, Germany)",0.9,Accept,Experimental Usage,"anti phospho-Histone H3 (pH3-Ser10, 06-570, 1:1000, Millipore)"
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)",0.9,Accept,Experimental Usage,S100β (Dako)
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)",0.9,Accept,Experimental Usage,MBP (Chemicon)
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)",0.9,Accept,Experimental Usage,BLBP (Millipore)
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",0.9,Accept,Experimental Usage,MAF (Imgenex)
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",0.9,Accept,Experimental Usage,"pS6, pERK (Cell Signaling)"
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",0.9,Accept,Experimental Usage,DEPTOR (Novus)
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako)",0.9,Accept,Experimental Usage,SOX9 (Santa Cruz)
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,Immunohistochemical analysis showed scattered S100 positivity in tumor cell nuclei,0.75,Accept,Experimental Usage,S100 antibody
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,strong and diffuse CD34 positivity in the tumor cell cytoplasm,0.75,Accept,Experimental Usage,CD34 antibody
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"Antibodies were sourced as follows: RHAMM (Epitomics), TPX2 (Novus), nestin (Covance)",0.9,Accept,Experimental Usage,RHAMM antibody (Epitomics)
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"Antibodies were sourced as follows: RHAMM (Epitomics), TPX2 (Novus), nestin (Covance)",0.9,Accept,Experimental Usage,TPX2 antibody (Novus)
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"Antibodies were sourced as follows: RHAMM (Epitomics), TPX2 (Novus), nestin (Covance)",0.9,Accept,Experimental Usage,nestin antibody (Covance)
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"nestin (Covance), Tuj1 (Covance), β-actin (Sigma), AURKA, phospho (p)-AURKA (Thr288)",0.9,Accept,Experimental Usage,Tuj1 antibody (Covance)
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"Tuj1 (Covance), β-actin (Sigma), AURKA, phospho (p)-AURKA (Thr288), p-histone H3 (Ser10)",0.9,Accept,Experimental Usage,β-actin antibody (Sigma)
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"β-actin (Sigma), AURKA, phospho (p)-AURKA (Thr288), p-histone H3 (Ser10), and caspase 9 (Cell Signalling)",0.9,Accept,Experimental Usage,AURKA antibody (Cell Signalling)
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"AURKA, phospho (p)-AURKA (Thr288), p-histone H3 (Ser10), and caspase 9 (Cell Signalling)",0.9,Accept,Experimental Usage,phospho-AURKA (Thr288) antibody (Cell Signalling)
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"phospho (p)-AURKA (Thr288), p-histone H3 (Ser10), and caspase 9 (Cell Signalling)",0.9,Accept,Experimental Usage,p-histone H3 (Ser10) antibody (Cell Signalling)
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"p-histone H3 (Ser10), and caspase 9 (Cell Signalling). The p-RHAMM (Thr703) polyclonal antibody",0.9,Accept,Experimental Usage,caspase 9 antibody (Cell Signalling)
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,"The dilutions of primary antibodies used in this study are as follows: GAP43 (rabbit, 1:1000, Abcam)",0.95,Accept,Experimental Usage,"GAP43 antibody (rabbit, 1:1000, Abcam)"
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,"The dilutions of primary antibodies used in this study are as follows: GAP43 (rabbit, 1:1000, Abcam) and S100β (rabbit, 1:5000, DAKO)",0.95,Accept,Experimental Usage,"S100β antibody (rabbit, 1:5000, DAKO)"
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,"Blots were probed overnight at 4 °C with either the neurofibromin antibody (Cell Signaling Technologies Cat. #: 14623 S; Danvers, MA, USA)",0.9,Accept,Experimental Usage,neurofibromin antibody (Cell Signaling Technologies Cat. #: 14623 S)
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Schwann cells were isolated from contaminating fibroblasts via p75 NGFR antibody-mediated magnetic cell selection,0.9,Accept,Experimental Usage,anti-p75 NGFR antibody
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"using mouse anti-Ki67 (1:2,000, BD Biosciences 556003 lot 8239549)",0.95,Accept,Experimental Usage,mouse anti-Ki67 (BD Biosciences 556003)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-CD8 (1:500, Cell Signaling Technology 98941T lot 5)",0.95,Accept,Experimental Usage,rabbit anti-CD8 (Cell Signaling Technology 98941T)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"goat anti-PDGFRα (1:2,000, R&D Systems AF1062 RRID: AB_2236897)",0.95,Accept,Experimental Usage,goat anti-PDGFRα (R&D Systems AF1062)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-S100β (1:2,000, Abcam ab52642 lot GR3215095-1)",0.95,Accept,Experimental Usage,rabbit anti-S100β (Abcam ab52642)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-IBA1 (1:1,000, Abcam ab178846 lot GR3185035-4)",0.95,Accept,Experimental Usage,rabbit anti-IBA1 (Abcam ab178846)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"mouse anti-BRN3A (1:200, Santa Cruz Biotechnology sc-8429 lot H1718)",0.95,Accept,Experimental Usage,mouse anti-BRN3A (Santa Cruz Biotechnology sc-8429)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-NLGN3, 1:500, Novus NBP1-90080 lot B118108",0.95,Accept,Experimental Usage,rabbit anti-NLGN3 (Novus NBP1-90080)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-β-actin, 1:10,000, Cell Signaling 4970 lot 15",0.95,Accept,Experimental Usage,rabbit anti-β-actin (Cell Signaling 4970)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-ADAM10, 1:250, Abcam ab124695 lot GR3244660-5",0.95,Accept,Experimental Usage,rabbit anti-ADAM10 (Abcam ab124695)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-cleaved caspase-3, 1:500, R&D Systems MAB835 lot KHK051810A",0.95,Accept,Experimental Usage,rabbit anti-cleaved caspase-3 (R&D Systems MAB835)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-caspase-3, 1:1,000, Cell Signaling 9662 lot 19",0.95,Accept,Experimental Usage,rabbit anti-caspase-3 (Cell Signaling 9662)
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,"Additionally, axons were identified by immunolabeling with tau 1 antibodies (not shown)",0.8,Accept,Experimental Usage,tau 1 antibodies
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"Primary antibodies for B-Actin(1:1000, Cat #8457S, Cell Signaling Technologies)",0.9,Accept,Experimental Usage,"B-Actin antibody (Cat #8457S, Cell Signaling Technologies)"
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"Vinculin(1:30000, Cat #V9264, Sigma Aldrich)",0.9,Accept,Experimental Usage,"Vinculin antibody (Cat #V9264, Sigma Aldrich)"
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"PTCH1(1:500,Cat#MAB41051, R&D systems)",0.9,Accept,Experimental Usage,"PTCH1 antibody (Cat#MAB41051, R&D systems)"
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"APC(1:500, Cat #15270, Abcam) were used.",0.9,Accept,Experimental Usage,"APC antibody (Cat #15270, Abcam)"
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"Primary antibodies against B-Actin (Cell Signaling Technologies #8457S, 1:10), PTCH1 (Cell Signaling Technologies #2468, 1:10)",0.9,Accept,Experimental Usage,PTCH1 antibody (Cell Signaling Technologies #2468)
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"GLI1 (Cell Signaling Technologies #3538, 1:10).",0.9,Accept,Experimental Usage,GLI1 antibody (Cell Signaling Technologies #3538)
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",0.85,Accept,Experimental Usage,Tuj-1
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",0.85,Accept,Experimental Usage,O4
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",0.85,Accept,Experimental Usage,GFAP
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"primary antibody (β-catenin, 1:100, Cell Signaling)",0.9,Accept,Experimental Usage,β-catenin antibody (Cell Signaling)
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage,activated β-catenin antibody (Cell Signaling)
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage,GSK3B antibody (Cell Signaling)
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage,AXIN1 antibody (Cell Signaling)
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage,GAPDH antibody (Cell Signaling)
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200)",0.9,Accept,Experimental Usage,"CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific)"
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200)",0.9,Accept,Experimental Usage,β-catenin (6B3) monoclonal antibody (Cell Signaling)
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,"incubated overnight with the primary anti-neurofibromin antibody (abcam, ab17963, 1/1000)",0.95,Accept,Experimental Usage,"anti-neurofibromin antibody (abcam, ab17963)"
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,"Anti-beta-Actin antibody (Santa Cruz Biotechnologies, sc4778, 1/10,000) was used to verify equal protein loading",0.9,Accept,Experimental Usage,"Anti-beta-Actin antibody (Santa Cruz Biotechnologies, sc4778)"
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,"anti-vinculin (abcam, ab129002, 1/1000) was used to verify equal protein loading",0.9,Accept,Experimental Usage,"anti-vinculin (abcam, ab129002)"
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"neurofibromin/NF1 (sc-67, sc-376886, Santa Cruz Biotechnology and ab238142, Abcam)",0.9,Accept,Experimental Usage,anti-neurofibromin antibody sc-67
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"neurofibromin/NF1 (sc-67, sc-376886, Santa Cruz Biotechnology and ab238142, Abcam)",0.9,Accept,Experimental Usage,anti-neurofibromin antibody sc-376886
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"neurofibromin/NF1 (sc-67, sc-376886, Santa Cruz Biotechnology and ab238142, Abcam)",0.9,Accept,Experimental Usage,anti-neurofibromin antibody ab238142
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"Flag (F7425, MilliporeSigma)",0.9,Accept,Experimental Usage,anti-Flag antibody F7425
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"GFP (ab1218, Abcam, Western blotting and Invitrogen, IP)",0.9,Accept,Experimental Usage,anti-GFP antibody ab1218
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"FBXW11/bTrCP2 (GTX33193, GeneTex and PA5-109715, Invitrogen, Thermo Fisher Scientific)",0.9,Accept,Experimental Usage,anti-FBXW11 antibody GTX33193
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"ERK1/2 (9102, Cell Signaling Technology)",0.9,Accept,Experimental Usage,anti-ERK1/2 antibody 9102
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"anti-pERK Thr202/Tyr204 (4377, Cell Signaling Technology)",0.9,Accept,Experimental Usage,anti-pERK antibody 4377
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,Blocking antibody (anti-CD16/CD32) was added to the cell suspensions and incubated 15 min.,0.8,Accept,Experimental Usage,anti-CD16/CD32 blocking antibody
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"The primary antibodies used included: mouse monoclonal (CA-4001) matrix metalloproteinase (MMP)2...dilution 1 : 1000; incubation overnight at 4 °C, Abcam",0.95,Accept,Experimental Usage,"mouse monoclonal (CA-4001) matrix metalloproteinase (MMP)2 (Abcam, Cambridge, Cambs., UK)"
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"rabbit monoclonal (EP1254) MMP9 (dilution 1 : 1000; incubation overnight at 4 °C, Abcam, Cambridge, Cambs., UK)",0.95,Accept,Experimental Usage,"rabbit monoclonal (EP1254) MMP9 (Abcam, Cambridge, Cambs., UK)"
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"MMP3 (dilution 1 : 50; incubation overnight at 4 °C, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA)",0.85,Accept,Experimental Usage,"MMP3 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA)"
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"GAPDH mouse mAb (6C5) (dilution 1 : 5000; incubation 1 h at room temperature; Advanced Immunochemical Inc., Long Beach, CA, USA)",0.9,Accept,Experimental Usage,"GAPDH mouse mAb (6C5) (Advanced Immunochemical Inc., Long Beach, CA, USA)"
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"Tumors were stained first with CD45-Vioblue direct antibody conjugate (clone REA747, Miltenyi Biotec) for 30 min at 4 °C.",0.9,Accept,Experimental Usage,"CD45-Vioblue direct antibody conjugate (clone REA747, Miltenyi Biotec)"
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"CD45 negative cells were stained with calcein AM (Life Technologies) for viability and CD24-APC (human antibody, clone REA832, Miltenyi Biotec)",0.9,Accept,Experimental Usage,"CD24-APC (human antibody, clone REA832, Miltenyi Biotec)"
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"and CD44-VioBlue (human antibody, clone REA690, Miltenyi Biotec) to sort subpopulations of viable non-immune cells.",0.9,Accept,Experimental Usage,"CD44-VioBlue (human antibody, clone REA690, Miltenyi Biotec)"
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"HLA-B (anti-HLA Class I ABC antibody, ab225636, Abcam, Cambridge, UK) for MHC I",0.9,Accept,Experimental Usage,"anti-HLA Class I ABC antibody, ab225636, Abcam"
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"and DPB1 (anti-MHC Class II antibody, ab55152, Abcam, Cambridge, UK) for MHC II",0.9,Accept,Experimental Usage,"anti-MHC Class II antibody, ab55152, Abcam"
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...with the following mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK)...",0.95,Accept,Experimental Usage,"CD13/FITC (22A5, Caltag Medsystems)"
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD14/PE (M5E2, BD Biosciences, CA, USA), CD34/FITC (581, BD Biosciences)...",0.95,Accept,Experimental Usage,"CD14/PE (M5E2, BD Biosciences)"
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD14/PE (M5E2, BD Biosciences, CA, USA), CD34/FITC (581, BD Biosciences), CD45/ALexa405...",0.95,Accept,Experimental Usage,"CD34/FITC (581, BD Biosciences)"
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5...",0.95,Accept,Experimental Usage,"CD45/ALexa405 (HI30, Caltag Medsystems)"
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC...",0.95,Accept,Experimental Usage,"CD90/PECy5 (5E10, BioLegend)"
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend), CD146/PE...",0.95,Accept,Experimental Usage,"CD105/APC (45A5A3, BioLegend)"
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences), CD271/APC...",0.95,Accept,Experimental Usage,"CD146/PE (P1H12, BD Biosciences)"
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences). Unstained cells were used as controls...",0.95,Accept,Experimental Usage,"CD271/APC (C401457, BD Biosciences)"
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...Expression of Ki-67 was evaluated immunohistochemically using mouse monoclonal antibody anti-Ki-67 (1:80; M7240; Dako Corporation, CA, USA)...",0.95,Accept,Experimental Usage,"anti-Ki-67 (M7240, Dako Corporation)"
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,incubated at 4 °C overnight in primary antibody; MKK3 (Cell Signaling #5674),0.95,Accept,Experimental Usage,MKK3 antibody (Cell Signaling #5674)
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,"p38 (Cell Signaling #9219), phospho-p38 (Cell Signaling # 4511)",0.95,Accept,Experimental Usage,p38 antibody (Cell Signaling #9219)
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,"p38 (Cell Signaling #9219), phospho-p38 (Cell Signaling # 4511)",0.95,Accept,Experimental Usage,phospho-p38 antibody (Cell Signaling #4511)
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,"phospho-ERK1/2 (Cell Signaling #9101), and β-Actin (Cell Signaling #3700)",0.95,Accept,Experimental Usage,phospho-ERK1/2 antibody (Cell Signaling #9101)
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,"phospho-ERK1/2 (Cell Signaling #9101), and β-Actin (Cell Signaling #3700)",0.95,Accept,Experimental Usage,β-Actin antibody (Cell Signaling #3700)
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"The following antibodies were used: anti-neurofibromin (#A300; Bethyl Laboratories, Montgomery, TX, USA)",0.9,Accept,Experimental Usage,anti-neurofibromin (#A300)
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",0.85,Accept,Experimental Usage,anti-phospho-Akt XP (#4060)
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",0.85,Accept,Experimental Usage,anti-Akt (#2938S)
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",0.85,Accept,Experimental Usage,anti-phospho-Erk XP (#4370)
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",0.85,Accept,Experimental Usage,anti-Erk (#4695S)
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-endothelial nitric oxide synthase (eNOS) (612392) and FITC-anti-CD31 (BD Laboratories, San Jose, CA, USA)",0.85,Accept,Experimental Usage,anti-phospho-endothelial nitric oxide synthase (eNOS) (612392)
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-endothelial nitric oxide synthase (eNOS) (612392) and FITC-anti-CD31 (BD Laboratories, San Jose, CA, USA)",0.85,Accept,Experimental Usage,FITC-anti-CD31
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"and anti-GAPDH (Novus, Littleton, CO, USA).",0.8,Accept,Experimental Usage,anti-GAPDH
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,"goat monoclonal Iba-1 antibody targeting microglia (1:300; Abcam, Cambridge, UK)",0.9,Accept,Experimental Usage,goat monoclonal Iba-1 antibody
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,"chicken polyclonal GFP antibody targeting eYFP (1:250; Abcam, Cambridge, UK)",0.85,Accept,Experimental Usage,chicken polyclonal GFP antibody
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,mouse anti-NeuN targeting neurons (1:00; Synaptic Systems),0.85,Accept,Experimental Usage,mouse anti-NeuN
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,"Iba-1 was visualized with donkey anti-goat IgG conjugated with Cy5 or Alexa488 fluorophores (both 1:200; Dianova, Hamburg, Germany)",0.8,Accept,Experimental Usage,donkey anti-goat IgG conjugated with Cy5
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,eYFP was visualized with donkey anti-chicken IgY conjugated with Alexa488 or Cy5 (both 1:200; Dianova),0.8,Accept,Experimental Usage,donkey anti-chicken IgY conjugated with Alexa488
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,"incubated with anti-mouse CD11b antibodies coupled to magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany)",0.85,Accept,Experimental Usage,anti-mouse CD11b antibodies coupled to magnetic beads
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"The following antibodies were purchased from Cell signaling Technologies: pERK (Catalogue # 4370), total ERK (Catalogue # 9102)",0.95,Accept,Experimental Usage,pERK (Catalogue # 4370)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"The following antibodies were purchased from Cell signaling Technologies: pERK (Catalogue # 4370), total ERK (Catalogue # 9102)",0.95,Accept,Experimental Usage,total ERK (Catalogue # 9102)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"pAKT (Catalogue # 4060), total AKT (Catalogue # 4691), Ubiquitin (Catalogue # 4289)",0.95,Accept,Experimental Usage,pAKT (Catalogue # 4060)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"pAKT (Catalogue # 4060), total AKT (Catalogue # 4691), Ubiquitin (Catalogue # 4289)",0.95,Accept,Experimental Usage,total AKT (Catalogue # 4691)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"total AKT (Catalogue # 4691), Ubiquitin (Catalogue # 4289), MYC (Catalogue # 18583)",0.95,Accept,Experimental Usage,Ubiquitin (Catalogue # 4289)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"Ubiquitin (Catalogue # 4289), MYC (Catalogue # 18583), pCHEK1 S296 (Catalogue # 90178)",0.95,Accept,Experimental Usage,MYC (Catalogue # 18583)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"MYC (Catalogue # 18583), pCHEK1 S296 (Catalogue # 90178), BMI1 (Catalogue # 5856)",0.95,Accept,Experimental Usage,pCHEK1 S296 (Catalogue # 90178)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"pCHEK1 S296 (Catalogue # 90178), BMI1 (Catalogue # 5856), H3K27Ac (Catalogue # 8173)",0.95,Accept,Experimental Usage,BMI1 (Catalogue # 5856)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"BMI1 (Catalogue # 5856), H3K27Ac (Catalogue # 8173), total H3 (Catalogue # 14269)",0.95,Accept,Experimental Usage,H3K27Ac (Catalogue # 8173)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"H3K27Ac (Catalogue # 8173), total H3 (Catalogue # 14269), CDK9 (Catalogue # 2316)",0.95,Accept,Experimental Usage,total H3 (Catalogue # 14269)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"total H3 (Catalogue # 14269), CDK9 (Catalogue # 2316), Vinculin (Catalogue # 4650)",0.95,Accept,Experimental Usage,CDK9 (Catalogue # 2316)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"CDK9 (Catalogue # 2316), Vinculin (Catalogue # 4650), CPNase (Catalogue # 5664)",0.95,Accept,Experimental Usage,Vinculin (Catalogue # 4650)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"Vinculin (Catalogue # 4650), CPNase (Catalogue # 5664) and MAG (Catalogue # 9043)",0.95,Accept,Experimental Usage,CPNase (Catalogue # 5664)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,CPNase (Catalogue # 5664) and MAG (Catalogue # 9043). Beta-Actin (Catalogue # NB600-501),0.95,Accept,Experimental Usage,MAG (Catalogue # 9043)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,MAG (Catalogue # 9043). Beta-Actin (Catalogue # NB600-501) was purchased from Novus,0.95,Accept,Experimental Usage,Beta-Actin (Catalogue # NB600-501)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"Beta-Actin (Catalogue # NB600-501) was purchased from Novus, pS2 RNApol II (Catalogue # 04-1571-1) from EMD Millipore",0.95,Accept,Experimental Usage,pS2 RNApol II (Catalogue # 04-1571-1)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"pS2 RNApol II (Catalogue # 04-1571-1) from EMD Millipore, SOX2 (Catalogue # MAB2018) from R&D systems",0.95,Accept,Experimental Usage,SOX2 (Catalogue # MAB2018)
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,SOX2 (Catalogue # MAB2018) from R&D systems and NG2 (Catalogue # PA5-17199) from Invitrogen,0.95,Accept,Experimental Usage,NG2 (Catalogue # PA5-17199)
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Antibodies used were: monoclonal anti-EGFR (1:250; Capralogics, Hardwick, MA)",0.9,Accept,Experimental Usage,"monoclonal anti-EGFR (1:250; Capralogics, Hardwick, MA)"
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"polyclonal anti-ErbB2 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA)",0.9,Accept,Experimental Usage,"polyclonal anti-ErbB2 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA)"
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,polyclonal anti-ErbB3 (1:250; Santa Cruz),0.9,Accept,Experimental Usage,polyclonal anti-ErbB3 (1:250; Santa Cruz)
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"polyclonal anti-merlin (1:250, Santa Cruz)",0.9,Accept,Experimental Usage,"polyclonal anti-merlin (1:250, Santa Cruz)"
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"and monoclonal anti-actin (BD Biosciences, San Jose, CA)",0.85,Accept,Experimental Usage,"monoclonal anti-actin (BD Biosciences, San Jose, CA)"
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Rabbit polyclonal anti-merlin (1:100; Santa Cruz Biotechnology, Santa Cruz, CA)",0.9,Accept,Experimental Usage,"Rabbit polyclonal anti-merlin (1:100; Santa Cruz Biotechnology, Santa Cruz, CA)"
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"cells were labeled with MPM-2 antibody (Upstate Biotechnology, Lake Placid, NY) for 1 h at 4°C",0.85,Accept,Experimental Usage,MPM-2 antibody
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,Detection of Ras was done by immunoblotting using the supplied pan-Ras antibody,0.85,Accept,Experimental Usage,pan-Ras antibody
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",0.85,Accept,Experimental Usage,Cyclin D1 antibody
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)",0.85,Accept,Experimental Usage,phospho-MEK1/2 [Ser217/221] antibody
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,"multiple predictive factors of recurrence, including age, female gender, and various histopathologic features, including the Ki-67/MIB-1 index.",0.75,Accept,Experimental Usage,Ki-67/MIB-1 index
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"Immunoblotting analysis was performed with antibodies specific for merlin (# HPA003097, Sigma-Aldrich; # sc331, Santa Cruz)",0.85,Accept,Experimental Usage,merlin antibody HPA003097
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"Immunoblotting analysis was performed with antibodies specific for merlin (# HPA003097, Sigma-Aldrich; # sc331, Santa Cruz)",0.85,Accept,Experimental Usage,merlin antibody sc331
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"antibodies specific for merlin (# HPA003097, Sigma-Aldrich; # sc331, Santa Cruz), p53 (# P6874, Sigma-Aldrich; # 2524, Cell Signaling)",0.85,Accept,Experimental Usage,p53 antibody P6874
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"p53 (# P6874, Sigma-Aldrich; # 2524, Cell Signaling), cyclinD1 (# C7464, Sigma-Aldrich)",0.85,Accept,Experimental Usage,p53 antibody 2524
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"MDM2 (# M43084 and # SAB4300601, Sigma-Aldrich), caspase-3 (# 9662, Cell Signaling)",0.85,Accept,Experimental Usage,MDM2 antibody M43084
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"MDM2 (# M43084 and # SAB4300601, Sigma-Aldrich), caspase-3 (# 9662, Cell Signaling)",0.85,Accept,Experimental Usage,MDM2 antibody SAB4300601
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,All antibodies used in this study were purchased from Peprotech (goat anti-CXCL12,0.8,Accept,Experimental Usage,goat anti-CXCL12 antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,purchased from Peprotech (goat anti-CXCL12 and rabbit anti CXCL12),0.8,Accept,Experimental Usage,rabbit anti CXCL12 antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Invitrogen (Rat anti-GFAP),0.8,Accept,Experimental Usage,Rat anti-GFAP antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,R&D (Goat anti-Endoglin),0.8,Accept,Experimental Usage,Goat anti-Endoglin antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Wako (rabbit anti-IBA-1),0.8,Accept,Experimental Usage,rabbit anti-IBA-1 antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",0.8,Accept,Experimental Usage,p-PKA substrate antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",0.8,Accept,Experimental Usage,pan-AKT antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",0.8,Accept,Experimental Usage,pS473-AKT antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Leinco (pan-CXCR4),0.8,Accept,Experimental Usage,pan-CXCR4 antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Sigma (mouse anti-CNPase),0.8,Accept,Experimental Usage,mouse anti-CNPase antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab,0.85,Accept,Development,phosphorylated CXCR4 (pCXCR4) antibody
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,The rabbit anti Olig2 antibody (DF-308) was a gift from Dr. Charles Stiles,0.85,Accept,Experimental Usage,rabbit anti Olig2 antibody (DF-308)
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,"Antibody against neurofibromin (cat. no. ab17963) was purchased from Abcam (Cambridge, UK)",0.9,Accept,Experimental Usage,anti-neurofibromin antibody (cat. no. ab17963)
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,Antibodies against GAPDH (cat. no. 5174S)...were obtained from Cell Signaling Technology,0.85,Accept,Experimental Usage,anti-GAPDH antibody (cat. no. 5174S)
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,phosphorylated PKA (cat. no. 5661S)...were obtained from Cell Signaling Technology,0.85,Accept,Experimental Usage,anti-phosphorylated PKA antibody (cat. no. 5661S)
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,PKA (cat. no. 4782S)...were obtained from Cell Signaling Technology,0.85,Accept,Experimental Usage,anti-PKA antibody (cat. no. 4782S)
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,phosphorylated CREB (cat. no. 9198S)...were obtained from Cell Signaling Technology,0.85,Accept,Experimental Usage,anti-phosphorylated CREB antibody (cat. no. 9198S)
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,CREB (cat. no. 9197T) were obtained from Cell Signaling Technology,0.85,Accept,Experimental Usage,anti-CREB antibody (cat. no. 9197T)
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,"Anti-P-glycoprotein primary antibody and Cy3-conjugated secondary antibody were purchased from Abcam (Cambridge, UK; ab170904) and Jackson ImmunoResearch",0.9,Accept,Experimental Usage,Anti-P-glycoprotein primary antibody (ab170904)
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,"Anti-P-glycoprotein primary antibody and Cy3-conjugated secondary antibody were purchased from Abcam (Cambridge, UK; ab170904) and Jackson ImmunoResearch",0.8,Accept,Experimental Usage,Cy3-conjugated secondary antibody
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,"Sections were then incubated overnight at 4°C in a humidified chamber with primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200))",0.85,Accept,Experimental Usage,S100 antibody (Santa Cruz 1:100)
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,"Sections were then incubated overnight at 4°C in a humidified chamber with primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200))",0.85,Accept,Experimental Usage,Ki67 antibody (Novocastra 1:200)
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,"The primary antibodies used in this study were: p-AKT S473 (Cell Signaling 1:100), p-4EBP (Cell Signaling 1:500), p-ERK (Cell Signaling 1:1000)",0.85,Accept,Experimental Usage,p-AKT S473 antibody (Cell Signaling 1:100)
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,"The primary antibodies used in this study were: p-AKT S473 (Cell Signaling 1:100), p-4EBP (Cell Signaling 1:500), p-ERK (Cell Signaling 1:1000)",0.85,Accept,Experimental Usage,p-4EBP antibody (Cell Signaling 1:500)
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,"The primary antibodies used in this study were: p-AKT S473 (Cell Signaling 1:100), p-4EBP (Cell Signaling 1:500), p-ERK (Cell Signaling 1:1000)",0.85,Accept,Experimental Usage,p-ERK antibody (Cell Signaling 1:1000)
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,"The primary antibodies used in this study were: p-AKT S473 (Cell Signaling 1:100), p-4EBP (Cell Signaling 1:500), p-ERK (Cell Signaling 1:1000), and GAPDH (Cell Signaling 1:2000)",0.85,Accept,Experimental Usage,GAPDH antibody (Cell Signaling 1:2000)
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"Immunocomplexes were precipitated with a mix of Protein A- and Protein G-Sepharose beads (1:1, Sigma) for 1 h at 4 °C before washing three times with IP buffer and denaturing with 2× SDS sample buffer. Lysates and immunoprecipitates were resolved on NuPAGE 3–8% Tris-Acetate (for Nf1) or NuPAGE 4–12% Bis-Tris gels (pERK/ERK/β-tubulin). After transfer to nitrocellulose membranes, blots were processed according to the Odyssey CLx protocol (LI-COR). Antibodies used for immunoblotting were: anti-Nf1 (mouse, mAb21, 1:10)",0.9,Accept,Experimental Usage,mAb21
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"anti-phospho-ERK (mouse, Sigma M8159, 1:2500)",0.9,Accept,Experimental Usage,Sigma M8159
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"total ERK (rabbit, CST 9102, 1:1000)",0.9,Accept,Experimental Usage,CST 9102
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"anti-β-tubulin (mouse, Developmental Studies Hybridoma Bank E7, 1:10,000)",0.85,Accept,Experimental Usage,E7
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"Antibodies used were: rabbit anti-GFP (Invitrogen, A11122, 1:4000)",0.9,Accept,Experimental Usage,Invitrogen A11122
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,"...Immunohistochemistry (IHC) for FOXR2 (1:100, SIGMA) was performed utilizing an immunohistochemical staining platform...",0.9,Accept,Experimental Usage,FOXR2 antibody (SIGMA)
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,"...transferred to PVDF membrane, and probed with antibodies against FOXR2 (SIGMA) and GAPDH (Cell Signaling Tech.) following manufacturers' protocols...",0.9,Accept,Experimental Usage,GAPDH antibody (Cell Signaling Tech.)
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,...Immunofluorescence on tissue sections and cell lines with antibodies probing FOXR2 (SIGMA) and CNPase (Santa Cruz) were carried out...,0.9,Accept,Experimental Usage,CNPase antibody (Santa Cruz)
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"using the following unconjugated antibodies: rabbit anti-human HER1 (Abcam, ab52894), rabbit anti-human HER2 (ZSGB-BIO, ZA-0023)",0.95,Accept,Experimental Usage,"rabbit anti-human HER1 (Abcam, ab52894)"
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human HER1 (Abcam, ab52894), rabbit anti-human HER2 (ZSGB-BIO, ZA-0023), rabbit anti-human VEGFR2 (CST, 9698S)",0.95,Accept,Experimental Usage,"rabbit anti-human HER2 (ZSGB-BIO, ZA-0023)"
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human HER2 (ZSGB-BIO, ZA-0023), rabbit anti-human VEGFR2 (CST, 9698S), rabbit anti-human B7H3 (CST, #14058)",0.95,Accept,Experimental Usage,"rabbit anti-human VEGFR2 (CST, 9698S)"
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human VEGFR2 (CST, 9698S), rabbit anti-human B7H3 (CST, #14058), rabbit anti-human CD171 (Abcam, ab208155)",0.95,Accept,Experimental Usage,"rabbit anti-human B7H3 (CST, #14058)"
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human B7H3 (CST, #14058), rabbit anti-human CD171 (Abcam, ab208155), rabbit anti-human EGFRvIII (ZSGB-BIO, ZA-0643)",0.95,Accept,Experimental Usage,"rabbit anti-human CD171 (Abcam, ab208155)"
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human CD171 (Abcam, ab208155), rabbit anti-human EGFRvIII (ZSGB-BIO, ZA-0643), rabbit anti-human TGFβ1 (Abcam, ab215715)",0.95,Accept,Experimental Usage,"rabbit anti-human EGFRvIII (ZSGB-BIO, ZA-0643)"
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human EGFRvIII (ZSGB-BIO, ZA-0643), rabbit anti-human TGFβ1 (Abcam, ab215715), rabbit anti-human PDL1 (Genetex, GTX104763)",0.95,Accept,Experimental Usage,"rabbit anti-human TGFβ1 (Abcam, ab215715)"
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human TGFβ1 (Abcam, ab215715), rabbit anti-human PDL1 (Genetex, GTX104763) and rabbit anti-human S100 (ZSGB-BIO, ZA-0225)",0.95,Accept,Experimental Usage,"rabbit anti-human PDL1 (Genetex, GTX104763)"
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human PDL1 (Genetex, GTX104763) and rabbit anti-human S100 (ZSGB-BIO, ZA-0225). After deparaffinization, rehydration",0.95,Accept,Experimental Usage,"rabbit anti-human S100 (ZSGB-BIO, ZA-0225)"
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"The antibodies used are as follows: S100β- Alexa Fluor 647 (Abcam, ab196175); Alexa Fluor 647 AffiniPure F (ab') 2 Fragment Goat Anti-Human IgG",0.95,Accept,Experimental Usage,"S100β- Alexa Fluor 647 (Abcam, ab196175)"
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014), CD45RO-PE (304206), and CCR7-Percp (353242) (all from BioLegend)",0.95,Accept,Experimental Usage,HER1-PE (352904)
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014), CD45RO-PE (304206), and CCR7-Percp (353242) (all from BioLegend)",0.95,Accept,Experimental Usage,CD4-PE (317410)
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014), CD45RO-PE (304206), and CCR7-Percp (353242) (all from BioLegend)",0.95,Accept,Experimental Usage,CD8a-APC (301014)
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014), CD45RO-PE (304206), and CCR7-Percp (353242) (all from BioLegend)",0.95,Accept,Experimental Usage,CD45RO-PE (304206)
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014), CD45RO-PE (304206), and CCR7-Percp (353242) (all from BioLegend)",0.95,Accept,Experimental Usage,CCR7-Percp (353242)
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Antibodies used in western blotting targeting β-actin (#13E5)...were purchased from Cell Signaling Technology,0.9,Accept,Experimental Usage,β-actin antibody (#13E5)
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Antibodies used in western blotting targeting...MEK1/2...were purchased from Cell Signaling Technology,0.85,Accept,Experimental Usage,MEK1/2 antibody
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,phospho-MEK1/2 (#41G9)...were purchased from Cell Signaling Technology,0.9,Accept,Experimental Usage,phospho-MEK1/2 antibody (#41G9)
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,phospho-ERK (#D13.14.4E)...were purchased from Cell Signaling Technology,0.9,Accept,Experimental Usage,phospho-ERK antibody (#D13.14.4E)
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,MMP1 (#E9S9N)...were purchased from Cell Signaling Technology,0.9,Accept,Experimental Usage,MMP1 antibody (#E9S9N)
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,NF1 (#D7R7D)...were purchased from Cell Signaling Technology,0.9,Accept,Experimental Usage,NF1 antibody (#D7R7D)
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,"Antibody for Aryl hydrocarbon receptor (AHR, #H-211) was from Santa Cruz Biotechnology",0.9,Accept,Experimental Usage,Aryl hydrocarbon receptor antibody (#H-211)
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,collagen I (#EPR7785) was from Abcam,0.9,Accept,Experimental Usage,collagen I antibody (#EPR7785)
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,anti-S100 protein antibody (Nichirei Biosciences Inc.),0.85,Accept,Experimental Usage,anti-S100 protein antibody
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,"Immunohistology analysis using Anti-CD31 (Abcam, ab7388) for vasculature",0.9,Accept,Experimental Usage,Anti-CD31
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,"Anti-S100B (Atlas Antibodies, HPA015768-100UL) antibodies for S100B protein",0.9,Accept,Experimental Usage,Anti-S100B
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Primary and secondary antibodies used were from Cell Signaling Technology: neurofibromin 1 (D7R7D) rabbit mAb 14623 (RRID: AB_2798543),0.95,Accept,Experimental Usage,neurofibromin 1 (D7R7D) rabbit mAb 14623 (RRID: AB_2798543)
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,"anti-rabbit IgG, and horseradish peroxidase–linked secondary 7074 (RRID: AB_2099233)",0.9,Accept,Experimental Usage,"anti-rabbit IgG, horseradish peroxidase–linked secondary 7074 (RRID: AB_2099233)"
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,β-Actin was probed as a loading control using β-actin (13E5) rabbit mAb #4970 (RRID: AB_2223172),0.9,Accept,Experimental Usage,β-actin (13E5) rabbit mAb #4970 (RRID: AB_2223172)
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"antibodies against S100 (monoclonal, mouse, 10 μg/mL, Ventana S100-4C4.9)",0.9,Accept,Experimental Usage,S100-4C4.9
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-Ki67 (monoclonal, mouse, 0.4 μg/mL, Ventana Ki-67-30.9)",0.9,Accept,Experimental Usage,Ki-67-30.9
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-CD34 (monoclonal, mouse, 0.8 μg/mL, Ventana QBEnd/10)",0.9,Accept,Experimental Usage,QBEnd/10
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-p53 (monoclonal, mouse, Ventana Bp-53-11)",0.9,Accept,Experimental Usage,Bp-53-11
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713)",0.9,Accept,Experimental Usage,725-4713
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9",0.9,Accept,Experimental Usage,V9
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4)",0.9,Accept,Experimental Usage,1A4
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein",0.95,Accept,Experimental Usage,Ki67 antigen antibody (Novocastra)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers)",0.95,Accept,Experimental Usage,glial fibrillary acidic protein antibody (Gfap; Sigma)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers), nestin (BD Bioscience)",0.95,Accept,Experimental Usage,Pten antibody (NeoMarkers)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Pten (NeoMarkers), nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling)",0.95,Accept,Experimental Usage,nestin antibody (BD Bioscience)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO)",0.95,Accept,Experimental Usage,phosphorylated Akt antibody (p-Akt; Cell Signaling)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO), Olig2 (Chemicon)",0.95,Accept,Experimental Usage,BrdUrd antibody (DAKO)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"BrdUrd (DAKO), Olig2 (Chemicon), or doublecortin (Santa Cruz)",0.95,Accept,Experimental Usage,Olig2 antibody (Chemicon)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Olig2 (Chemicon), or doublecortin (Santa Cruz). We used microwave antigen retrieval",0.95,Accept,Experimental Usage,doublecortin antibody (Santa Cruz)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Antibodies used were against β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon)",0.95,Accept,Experimental Usage,β3-tubulin antibody (TuJ1; Covance)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin",0.95,Accept,Experimental Usage,Gfap antibody (Dako)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Gfap (Dako), CNPase (Chemicon), or nestin",0.95,Accept,Experimental Usage,CNPase antibody (Chemicon)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma)",0.95,Accept,Experimental Usage,Pten antibody (Cell Signaling)
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma)",0.95,Accept,Experimental Usage,β-actin antibody (Sigma)
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,optic nerve sections were incubated with polyclonal anti-S100A10 antibodies (1:1000; R&D Systems) followed by horseradish peroxidase-conjugated secondary antibodies,0.9,Accept,Experimental Usage,polyclonal anti-S100A10 antibodies
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,"followed by horseradish peroxidase-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA, USA) in combination with Vectastain Elite ABC development",0.8,Accept,Experimental Usage,horseradish peroxidase-conjugated secondary antibodies
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T), Caspase-3 (9662S)",0.9,Accept,Experimental Usage,Cdk1 (77055S)
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T), Caspase-3 (9662S)",0.9,Accept,Experimental Usage,phospho-Cdk1 Tyr15 (9111T)
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T), Caspase-3 (9662S)",0.9,Accept,Experimental Usage,Caspase-3 (9662S)
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Cleaved Caspase-3 (9661S), Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)",0.9,Accept,Experimental Usage,Cleaved Caspase-3 (9661S)
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Cleaved Caspase-3 (9661S), Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)",0.9,Accept,Experimental Usage,Histone H3 (9715S)
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Cleaved Caspase-3 (9661S), Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)",0.9,Accept,Experimental Usage,Acetyl-Histone H3 Lys18 (9675S)
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T), p70S6 Kinase (9202S)",0.9,Accept,Experimental Usage,SAPK/JNK (9252T)
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T), p70S6 Kinase (9202S)",0.9,Accept,Experimental Usage,phospho-SAPK/JNK Thr183/Tyr185 (4668T)
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T), p70S6 Kinase (9202S)",0.9,Accept,Experimental Usage,p70S6 Kinase (9202S)
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,phospho-p70 Thr389 S6 Kinase (9234S)
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"the samples were incubated in mouse monoclonal anti-BrdU (1:800, Sigma-Aldrich, St. Louis, MO) and rabbit anti-S100 (1:800, Sigma-Aldrich, St. Louis, MO)",0.85,Accept,Experimental Usage,mouse monoclonal anti-BrdU
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"the samples were incubated in mouse monoclonal anti-BrdU (1:800, Sigma-Aldrich, St. Louis, MO) and rabbit anti-S100 (1:800, Sigma-Aldrich, St. Louis, MO)",0.85,Accept,Experimental Usage,rabbit anti-S100
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"secondary antibodies (anti-mouse Alexa Fluor 568 and anti-rabbit Alexa Fluor 488, 1:800 each, Invitrogen, Carlsbad, CA) diluted in PBS were applied",0.8,Accept,Experimental Usage,anti-mouse Alexa Fluor 568
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"secondary antibodies (anti-mouse Alexa Fluor 568 and anti-rabbit Alexa Fluor 488, 1:800 each, Invitrogen, Carlsbad, CA) diluted in PBS were applied",0.8,Accept,Experimental Usage,anti-rabbit Alexa Fluor 488
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"co-incubation with AlexaFlour488 conjugated-pS6 (Ser240/244) antibody (Cell Signaling Technology; Beverly, MA)",0.9,Accept,Experimental Usage,AlexaFlour488 conjugated-pS6 (Ser240/244) antibody
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)",0.85,Accept,Experimental Usage,phospho-S6 (S240/244)
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"phospho-Akt (S473), Akt, phospho-NDRG1 (T346)",0.85,Accept,Experimental Usage,phospho-Akt (S473)
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"SGK1, phospho-PAK1 (S144), PAK1, and 4EBP1 were from Cell Signaling Technology",0.8,Accept,Experimental Usage,SGK1
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Other antibodies included NDRG1 (Abcam; Cambridge, MA)",0.85,Accept,Experimental Usage,NDRG1 (Abcam)
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Rac1 (BD Biosciences; San Jose, CA)",0.85,Accept,Experimental Usage,Rac1 (BD Biosciences)
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Rheb (3M6 monoclonal; a generous gift from Richard Lamb, University of Liverpool, U.K.)",0.9,Accept,Experimental Usage,Rheb (3M6 monoclonal)
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,the NF2 polyclonal C26 antibody has been described,0.9,Accept,Experimental Usage,NF2 polyclonal C26 antibody
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,...They were all S100-positive by immunostaining. The main clinical and histological characteristics of the 9 patients with MPNSTs are shown in Table 1. The MPNSTs all arose from plexiform neurofibromas and showed very weak S100 immunostaining...,0.75,Accept,Experimental Usage,S100 immunostaining
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"anti-NF1 D7R7D #14624 (Cell Signaling, rabbit, 2% BSA, 1:1000, overnight, 4 °C)",0.95,Accept,Experimental Usage,anti-NF1 D7R7D #14624
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"anti-tubulin B-1-2-5 (Santa Cruz, mouse, 2% milk, 1:10000, 1 h, RT)",0.9,Accept,Experimental Usage,anti-tubulin B-1-2-5
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"anti-EGFR D38B1 #4267 (Cell Signaling, rabbit, 2% milk, 1:1000–1:2000, 1 h, RT)",0.9,Accept,Experimental Usage,anti-EGFR D38B1 #4267
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"p-ERK ½ (p44/42 MAPK) #9101 (Cell Signaling, rabbit, 2% BSA, 1:2000, overnight, 4 °C)",0.9,Accept,Experimental Usage,p-ERK ½ (p44/42 MAPK) #9101
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"SUZ12 D39F6 #3737 (Cell Signaling, rabbit, 2% milk, 1:1000, overnight, 4 °C)",0.9,Accept,Experimental Usage,SUZ12 D39F6 #3737
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include Pak1; Pak2; Mek1/2; phospho-MEK1 (Ser298); Erk1/2; phospho-Erk1/2 (Thr202/Tyr204); Akt; phospho-Akt (Thr308); Merlin (Cell Signaling Technology),0.8,Accept,Experimental Usage,Pak1 antibody
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include Pak1; Pak2; Mek1/2; phospho-MEK1 (Ser298); Erk1/2; phospho-Erk1/2 (Thr202/Tyr204); Akt; phospho-Akt (Thr308); Merlin (Cell Signaling Technology),0.8,Accept,Experimental Usage,Pak2 antibody
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include Pak1; Pak2; Mek1/2; phospho-MEK1 (Ser298); Erk1/2; phospho-Erk1/2 (Thr202/Tyr204); Akt; phospho-Akt (Thr308); Merlin (Cell Signaling Technology),0.9,Accept,Experimental Usage,Merlin antibody
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,phospho-Pak1–3 (Ser141; Invitrogen); GST (Santa Cruz Biotechnology); and β-actin (Sigma),0.85,Accept,Experimental Usage,phospho-Pak1–3 (Ser141) antibody
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,Antibodies against DUSP6 (# ab76310) were from Abcam,0.9,Accept,Experimental Usage,DUSP6 antibody (ab76310)
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,Antibodies against cyclin D1 (sc-718 and sc-8396) were from Santa Cruz Biotechnology,0.9,Accept,Experimental Usage,cyclin D1 antibody (sc-718)
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,Antibodies against cyclin D1 (sc-718 and sc-8396) were from Santa Cruz Biotechnology,0.9,Accept,Experimental Usage,cyclin D1 antibody (sc-8396)
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibody, anti-Ki-67 (1:200 dilution; # Ab16667, lot number GR3185488–1, Abcam) was applied at 36 °C for 60 minutes",0.9,Accept,Experimental Usage,Ki-67 antibody (Ab16667)
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,"...The following antibodies were used for immunodetection: panendothelial cell antigen (550563, BD Pharmingen, USA)...",0.9,Accept,Experimental Usage,"panendothelial cell antigen (550563, BD Pharmingen, USA)"
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,"...and anti-ratAlexa555 (A11081, Invitrogen, USA). Sections were analyzed with confocal microscopy...",0.9,Accept,Experimental Usage,"anti-ratAlexa555 (A11081, Invitrogen, USA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"incubated overnight at 4°C with antibody: anti-S100β, Dako, Carpinteria, CA",0.9,Accept,Experimental Usage,"anti-S100β (Dako, Carpinteria, CA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Ki67 (Novacastra Leica Microsystems, Buffalo Grove, IL) or anti-P-Stat3 (Y705)",0.9,Accept,Experimental Usage,"Ki67 (Novacastra Leica Microsystems, Buffalo Grove, IL)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",0.9,Accept,Experimental Usage,"anti-P-Stat3 (Y705) (Cell Signaling, Danvers, MA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",0.9,Accept,Experimental Usage,"anti-cleaved caspase 3 (Cell Signaling, Danvers, MA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",0.9,Accept,Experimental Usage,"β-catenin (Cell Signaling, Danvers, MA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3",0.85,Accept,Experimental Usage,"P-Jak2 (Cell Signaling, MA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3",0.85,Accept,Experimental Usage,"Jak2 (Cell Signaling, MA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3",0.85,Accept,Experimental Usage,"P-Stat3 (Cell Signaling, MA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3",0.85,Accept,Experimental Usage,"Stat3 (Cell Signaling, MA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.85,Accept,Experimental Usage,"P-β-catenin (Cell Signaling, MA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.85,Accept,Experimental Usage,"P-GSK3β (Cell Signaling, MA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.85,Accept,Experimental Usage,"GSK3β (Cell Signaling, MA)"
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.85,Accept,Experimental Usage,"β-actin (Cell Signaling, MA)"
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"Mouse Fc receptor was blocked by TruStain FcX™ (anti-mouse CD16/32) antibody (BioLegend, Cat# 101320)",0.9,Accept,Experimental Usage,TruStain FcX™ (anti-mouse CD16/32) antibody
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 102410, 116208 and 103112)",0.9,Accept,Experimental Usage,PE-conjugated CD31 antibody
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 102410, 116208 and 103112)",0.9,Accept,Experimental Usage,PE-conjugated Ter119 antibody
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 102410, 116208 and 103112)",0.9,Accept,Experimental Usage,PE-conjugated CD45 antibody
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,cell suspensions were stained with antibodies against p75 (Ab 1554; Chemicon),0.9,Accept,Experimental Usage,p75 antibody (Ab 1554; Chemicon)
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,"antibodies against p75 (Ab 1554; Chemicon) and α 4 integrin (Becton-Dickinson, San Jose, CA)",0.85,Accept,Experimental Usage,α4 integrin antibody (Becton-Dickinson)
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,"Total BM cells were labeled with biotin-conjugated α-Lin Abs, consisting of α-CD3e, α-CD11b, α-CD45R/B220, α-Ly6G/Ly6C, and α-TER-119 Abs",0.8,Accept,Experimental Usage,biotin-conjugated α-Lin Abs
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"immunostaining with Ki67 (BD PharMingen, Pasadena CA) antibodies was performed as previously described",0.85,Accept,Experimental Usage,Ki67 antibody (BD PharMingen)
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"Primary phospho-histone-H3 (Ser 10) antibody was purchased from Abcam, Inc.",0.85,Accept,Experimental Usage,phospho-histone-H3 (Ser 10) antibody (Abcam)
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"All antibodies were purchased from Cell Signaling Technology (Beverly, MD) and used at a 1:1,000 dilution",0.8,Accept,Experimental Usage,Cell Signaling Technology antibodies
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"using α-tubulin (Sigma, St. Louis MO), β-actin or non-phospho-STAT3, AKT, S6, and 4EBP1 antibodies for normalization",0.85,Accept,Experimental Usage,α-tubulin antibody (Sigma)
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",0.8,Accept,Experimental Usage,p-AKT antibody
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",0.8,Accept,Experimental Usage,total AKT antibody
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",0.8,Accept,Experimental Usage,β-Actin antibody
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"Bound RNA and protein of interest is immunoprecipitated using the Ago2 antibody (Cell Signaling Technology, Beverly, MA, USA) at a dilution of 1:50",0.8,Accept,Experimental Usage,Ago2 antibody
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,Rabbit anti-Etv5 antibody (Novus Biologicals) was diluted at 1:100 for immunohistochemistry.,0.85,Accept,Experimental Usage,Rabbit anti-Etv5 antibody (Novus Biologicals)
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,Anti-ERK1/2 (p44/42 MAPK (Erk1/2); Cell Signaling Technology; 1:1000),0.85,Accept,Experimental Usage,Anti-ERK1/2 (p44/42 MAPK (Erk1/2))
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,anti-phopho ERK1/2 (Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204); Cell Signaling Technology; 1:1000),0.85,Accept,Experimental Usage,anti-phopho ERK1/2 (Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204))
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,anti-GAPDH; Santa Cruz Biotechnology Inc.; 1:3000),0.8,Accept,Experimental Usage,anti-GAPDH
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,"...incubated the dissociated mouse DRG/neurofibroma cell suspensions with anti-mouse monoclonal antibodies against CD11b (8G12/HPCA-2, Becton–Dickinson)...",0.9,Accept,Experimental Usage,"anti-mouse monoclonal antibodies against CD11b (8G12/HPCA-2, Becton–Dickinson)"
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,"...bound to allophycocyanin (APC) anti-p75/NGFR (C40-1457, Becton–Dickinson) bound to phycoerythrin (PE)...",0.9,Accept,Experimental Usage,"anti-p75/NGFR (C40-1457, Becton–Dickinson)"
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,"...anti-p75/NGFR (C40-1457, Becton–Dickinson) bound to phycoerythrin (PE), anti-F4/80 bound to Cy5.5 on ice...",0.85,Accept,Experimental Usage,anti-F4/80 bound to Cy5.5
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,...0.1 mL DMEM medium containing 10% FBS or 50 ng/mL Anti-CSF1 (R&D Systems MAB4161) in the same medium...,0.9,Accept,Experimental Usage,Anti-CSF1 (R&D Systems MAB4161)
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,"We assessed the purity of Schwann cell cultures by immunofluorescent staining with an S-100β antibody (Serra et al, 2000).",0.85,Accept,Experimental Usage,S-100β antibody
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,"probed membranes with anti-SOX9 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:700), then re-probed with anti-β-actin",0.95,Accept,Experimental Usage,"anti-SOX9 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:700)"
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,"then re-probed with anti-β-actin (Cell Signaling Technology, Inc. #4967) as a loading control",0.95,Accept,Experimental Usage,"anti-β-actin (Cell Signaling Technology, Inc. #4967)"
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,"We performed SOX9 immunohistochemistry on formalin-fixed, paraffin-embedded sections with polyclonal anti-SOX9 antibody (Abcam, Cambridge, UK)",0.95,Accept,Experimental Usage,"polyclonal anti-SOX9 antibody (Abcam, Cambridge, UK)"
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,"Primary antibodies included N-Terminal NF1 (Cell Signaling cat# D7R7D 1:1000), beta-actin (Cell Signaling cat# 3700 1:10000)",0.9,Accept,Experimental Usage,N-Terminal NF1 (Cell Signaling cat# D7R7D)
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,"Primary antibodies included N-Terminal NF1 (Cell Signaling cat# D7R7D 1:1000), beta-actin (Cell Signaling cat# 3700 1:10000)",0.85,Accept,Experimental Usage,beta-actin (Cell Signaling cat# 3700)
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,"Primary antibodies included N-Terminal NF1 (Cell Signaling cat# D7R7D 1:1000), beta-actin (Cell Signaling cat# 3700 1:10000), p-ERK (Cell Signaling cat# 9101 1:1000)",0.85,Accept,Experimental Usage,p-ERK (Cell Signaling cat# 9101)
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,"p-ERK (Cell Signaling cat# 9101 1:1000), and total ERK (Cell Signaling cat# 9102 1:1000). The secondary antibody was HRP-tagged from Santa Cruz",0.85,Accept,Experimental Usage,total ERK (Cell Signaling cat# 9102)
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,"incubated with anti-KIF11 antibody (Proteintech), anti-KIF15 antibody (Proteintech)",0.9,Accept,Experimental Usage,anti-KIF11 antibody (Proteintech)
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,"incubated with anti-KIF11 antibody (Proteintech), anti-KIF15 antibody (Proteintech)",0.9,Accept,Experimental Usage,anti-KIF15 antibody (Proteintech)
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,"or Ki67 (Ventana Medical Systems), and a horseradish peroxidase–conjugated secondary antibody",0.9,Accept,Experimental Usage,Ki67 (Ventana Medical Systems)
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,with anti-α-tubulin (Sigma-Aldrich) during 1 h at room temperature,0.9,Accept,Experimental Usage,anti-α-tubulin (Sigma-Aldrich)
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,incubated with 1:100 of anti-α-tubulin-Alexa488 antibody (Life Technologies) for 45 min,0.9,Accept,Experimental Usage,anti-α-tubulin-Alexa488 antibody (Life Technologies)
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,using the Annexin-V-Alexa Fluor 568 antibody (Roche and Life Technologies),0.9,Accept,Experimental Usage,Annexin-V-Alexa Fluor 568 antibody (Roche and Life Technologies)
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,"PGDS immunohistochemistry was carried out on adjacent paraffin sections using affinity‐purified rabbit polyclonal antibodies (1:500; Santa Cruz, CA, USA sc‐14825)",0.9,Accept,Experimental Usage,PGDS antibody (Santa Cruz sc-14825)
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",0.9,Accept,Experimental Usage,phospho-AKT (S473) antibody
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",0.9,Accept,Experimental Usage,total AKT antibody
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",0.9,Accept,Experimental Usage,monoclonal rabbit anti-phospho-S6K (T389) antibody
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,Total S6K1 antibody was used as previously described,0.85,Accept,Experimental Usage,total S6K1 antibody
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,Sections were incubated with rat anti-CD31 antibodies (BD bioscience) at 1:40 dilution for 60 min at room temperature,0.9,Accept,Experimental Usage,rat anti-CD31 antibodies
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"For Mib1 detection, paraffin sections were treated with TRS or antigen retrieval followed by a prediluted Mib1 antibody (DAKO)",0.9,Accept,Experimental Usage,Mib1 antibody
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,"Antibodies were obtained from Peprotech (CXCL12), Clontech (Dsred (mCherry)), Invitrogen (GFAP)",0.9,Accept,Experimental Usage,CXCL12 antibody (Peprotech)
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,"Antibodies were obtained from Peprotech (CXCL12), Clontech (Dsred (mCherry)), Invitrogen (GFAP)",0.9,Accept,Experimental Usage,GFAP antibody (Invitrogen)
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,"Abcam (PDE4A & 58kD Golgi marker), Pharmingen (LCA), Wako (IBA-1)",0.9,Accept,Experimental Usage,PDE4A antibody (Abcam)
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Antibody directed against Olig2 (DF-308) was a gift of Dr. Charles Stiles (Dana Farber Cancer Institute),0.85,Accept,Experimental Usage,Olig2 antibody (DF-308)
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab and previously described,0.8,Accept,Experimental Usage,phosphorylated CXCR4 antibody (pCXCR4)
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"incubated overnight at 4°C with primary antibodies diluted in blocking buffer: CD31 (3528S, 1:100, Cell Signaling)",0.95,Accept,Experimental Usage,"CD31 antibody (3528S, Cell Signaling)"
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"Survivin (MA5-15077, 1:200, Invitrogen), and CENPF (PA5-84637, 1:200, Invitrogen)",0.95,Accept,Experimental Usage,"Survivin antibody (MA5-15077, Invitrogen)"
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"Survivin (MA5-15077, 1:200, Invitrogen), and CENPF (PA5-84637, 1:200, Invitrogen)",0.95,Accept,Experimental Usage,"CENPF antibody (PA5-84637, Invitrogen)"
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"and H3K27me3 (9733S, 1:100, Cell Signaling). Sections were then incubated with secondary antibodies",0.95,Accept,Experimental Usage,"H3K27me3 antibody (9733S, Cell Signaling)"
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"Immunoblots were carried out using antibodies specific to CENPF (ab223847, 1:1000 dilution, Abcam)",0.95,Accept,Experimental Usage,"CENPF antibody (ab223847, Abcam)"
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"Survivin (MA5-15077, 1:1000, Invitrogen) and Vinculin (ab219649, 1:1000 dilution, Abcam)",0.95,Accept,Experimental Usage,"Vinculin antibody (ab219649, Abcam)"
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,"followed by either Alexa-Fluor-tagged secondary antibodies (Invitrogen, Grand Island, NY) and DAPI counterstaining",0.8,Accept,Experimental Usage,Alexa-Fluor-tagged secondary antibodies
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,DAPI counterstaining or biotinylated secondary antibodies and Vectastain Elite ABC development,0.8,Accept,Experimental Usage,biotinylated secondary antibodies
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution.",0.85,Accept,Experimental Usage,rabbit anti-EGFR (Cell Signaling)
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution.",0.85,Accept,Experimental Usage,Notch1 (Cell Signaling)
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution.",0.9,Accept,Experimental Usage,rabbit anti S518-Merlin (Abcam and Cell Signaling)
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",0.8,Accept,Experimental Usage,"rabbit anti-Na+,K+-ATPase (Cell Signaling)"
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",0.8,Accept,Experimental Usage,GAPDH (Cell Signaling)
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",0.8,Accept,Experimental Usage,PARP (Cell Signaling)
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,An actin immunocytochemistry assay was performed to study the cytoskeletal organization after PMO treatment using Phalloidin (Molecular Probes),0.85,Accept,Experimental Usage,Phalloidin
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,"Flag expression was assessed by western blot (Monoclonal ANTI-FLAG M2 antibody, Sigma-Aldrich, St. Louis, MO)",0.9,Accept,Experimental Usage,Monoclonal ANTI-FLAG M2 antibody
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,"The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316)",0.95,Accept,Experimental Usage,"anti-NeuroD1 (Abcam, ab109224)"
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,"The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316)",0.95,Accept,Experimental Usage,"anti-β-actin (Sigma, A5316)"
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"Ras was detected with a 1:250 dilution of anti-pan Ras monoclonal antibody (BD Transduction Laboratories, San Jose, CA)",0.9,Accept,Experimental Usage,anti-pan Ras monoclonal antibody (BD Transduction Laboratories)
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"Caspase-3 was detected with a 1:1000 dilution of anti-Caspase-3 polycolonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)",0.9,Accept,Experimental Usage,anti-Caspase-3 polycolonal antibody (Santa Cruz Biotechnology)
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"Retinoblastoma protein (pRb) phosphorylated Serine 780 was detected with a 1:1000 dilution of anti-Phospho-Rb Ser 780 polyclonal antibody (Cell Signaling Technology, Danvers, MA)",0.9,Accept,Experimental Usage,anti-Phospho-Rb Ser 780 polyclonal antibody (Cell Signaling Technology)
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"β-Tubulin was immunoblotted with a 1:2000 dilution of the E7 monoclonal antibody (Developmental Studies Hybridoma Bank, Iowa City, IA)",0.9,Accept,Experimental Usage,E7 monoclonal antibody (Developmental Studies Hybridoma Bank)
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,incubated with primary antibodies overnight at 4°C: S100-fluorescein isothiocyanate (FITC) (major protein expressed by C6 cells),0.8,Accept,Experimental Usage,S100-FITC antibody
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,"β-tubulin III-FITC (neurofibroma presence), Ki67-FITC (proliferation marker)",0.8,Accept,Experimental Usage,β-tubulin III-FITC antibody
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,"Ki67-FITC (proliferation marker), Vimentin-antigen presenting cell (APC)",0.8,Accept,Experimental Usage,Ki67-FITC antibody
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,"Vimentin-antigen presenting cell (APC) (expressed by C6 cells), and Foxp3-APC and CD45",0.8,Accept,Experimental Usage,Vimentin-APC antibody
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,Foxp3-APC and CD45 (immune response markers),0.8,Accept,Experimental Usage,Foxp3-APC antibody
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,Foxp3-APC and CD45 (immune response markers),0.8,Accept,Experimental Usage,CD45 antibody
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,"Human S-100 A and B protein was detected using rabbit antiserum (Dako Corp, Carpinteria, Calif) diluted with phosphate-buffered saline",0.8,Accept,Experimental Usage,"rabbit antiserum (Dako Corp, Carpinteria, Calif)"
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,The rabbit anti-S-100 antibodies were detected using affinity purified biotinylated F(ab')2 swine anti-rabbit IgG (Dako),0.8,Accept,Experimental Usage,biotinylated F(ab')2 swine anti-rabbit IgG (Dako)
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,"followed by horseradish peroxidase-conjugated streptavidin (Dako), both diluted in 5% PBS/BSA",0.75,Accept,Experimental Usage,horseradish peroxidase-conjugated streptavidin (Dako)
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,"Fluorescein-conjugated IB4 (Vector Laboratories, Burlingame, Calif) diluted in PBS, pH = 7.2, containing 5% BSA, was applied to the sections",0.8,Accept,Experimental Usage,"Fluorescein-conjugated IB4 (Vector Laboratories, Burlingame, Calif)"
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling) and p-DARPP32 (Abcam) antibodies",0.85,Accept,Experimental Usage,DARPP32 antibody
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling) and p-DARPP32 (Abcam) antibodies",0.85,Accept,Experimental Usage,p-MAPK antibody
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling) and p-DARPP32 (Abcam) antibodies",0.85,Accept,Experimental Usage,total MAPK antibody
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling) and p-DARPP32 (Abcam) antibodies",0.85,Accept,Experimental Usage,p-DARPP32 antibody
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,"The cells were labeled with Alexa Fluor 647-conjugated anti-phospho-ERK1/2 primary antibody (Cell Signaling Technology, MA, USA) using 1:50 dilution",0.9,Accept,Experimental Usage,Alexa Fluor 647-conjugated anti-phospho-ERK1/2 primary antibody
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,"Plasma VEGF and soluble VEGFR2 (sVEGFR2) were quantified...using commercial available human VEGF and sVEGFR2 immunoassay kits (Quantikine™, R&D Systems, Minneapolis, MN).",0.85,Accept,Experimental Usage,Quantikine™ human VEGF immunoassay kit
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,"Plasma VEGF and soluble VEGFR2 (sVEGFR2) were quantified...using commercial available human VEGF and sVEGFR2 immunoassay kits (Quantikine™, R&D Systems, Minneapolis, MN).",0.85,Accept,Experimental Usage,Quantikine™ human sVEGFR2 immunoassay kit
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,The embryos were incubated in anti-pH3 antibody overnight at 4°C.,0.85,Accept,Experimental Usage,anti-pH3 antibody
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,"The samples were washed in PBS–Triton-X100 (4×30 min) at room temperature and incubated in a secondary antibody (Thermo Fisher Scientific, A21202) for 4 h at room temperature.",0.9,Accept,Experimental Usage,A21202
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,Anti-Sox10 antibody staining on HCR-processed sections was performed according to Kamenev et al. (2021).,0.85,Accept,Experimental Usage,anti-Sox10 antibody
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,"Subsequently, the blot was incubated with a 1:1000 dilution of anti-merlin antibody overnight at 4°C.",0.85,Accept,Experimental Usage,anti-merlin antibody
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,"the membrane was washed with 0.1% TBST and incubated with the corresponding secondary antibody conjugated to horseradish peroxidase (GE Life Sciences, NA934) at 1:10,000 dilution",0.9,Accept,Experimental Usage,NA934
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"using the following Biolegend antibodies and stains: anti-human HLA-A,B,C (311405)",0.85,Accept,Experimental Usage,"anti-human HLA-A,B,C (311405)"
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"anti-mouse H-2 (125505), Mouse IgG1, κ Isotype Ctrl (FC) Antibody",0.85,Accept,Experimental Usage,anti-mouse H-2 (125505)
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"using the following antibodies: human nuclei (ab254080, Abcam)",0.85,Accept,Experimental Usage,"human nuclei (ab254080, Abcam)"
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology)",0.85,Accept,Experimental Usage,"Ki-67 (RM9106S1, Fisher Scientific)"
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"S-100 b (sc-393919, Santa Cruz Biotechnology), H3K27me3 (9733, Cell Signaling Technologies)",0.85,Accept,Experimental Usage,"S-100 b (sc-393919, Santa Cruz Biotechnology)"
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies)",0.85,Accept,Experimental Usage,"H3K27me3 (9733, Cell Signaling Technologies)"
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"pERK (4370, Cell Signaling Technologies). Microtissues were assessed for compaction",0.85,Accept,Experimental Usage,"pERK (4370, Cell Signaling Technologies)"
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,"A recombinant anti-FAP antibody (clone ab207178, Abcam, Cambridge, UK) was applied at a dilution of 1:250",0.95,Accept,Experimental Usage,"anti-FAP antibody (clone ab207178, Abcam)"
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"Slides were treated with primary antibodies for LAMA2 (Abnova (Catalog #: H00003908-M01), 1:1000)",0.95,Accept,Experimental Usage,LAMA2 antibody (Abnova H00003908-M01)
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"SLC22A3 (Novus Biologicals (Catalog #: NBP1-83976), 1:750)",0.95,Accept,Experimental Usage,SLC22A3 antibody (Novus Biologicals NBP1-83976)
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"PRRX1 (Thermo Fisher Scientific (Catalog#: MA5-26580), 1:200)",0.95,Accept,Experimental Usage,PRRX1 antibody (Thermo Fisher Scientific MA5-26580)
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"SOX10 (Roche (Catalog#: 760-4968), pre-diluted kit)",0.95,Accept,Experimental Usage,SOX10 antibody (Roche 760-4968)
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling), pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling)",0.85,Accept,Experimental Usage,"pDARPP32 (1:500, Cell Signaling)"
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling), pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling)",0.85,Accept,Experimental Usage,"DARPP32 (1:1000, Cell Signaling)"
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling), pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling)",0.85,Accept,Experimental Usage,"pERK1/2 (1:1000, Cell Signaling)"
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling), pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling)",0.85,Accept,Experimental Usage,"ERK1/2 (1:1000, Cell Signaling)"
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"using an anti-Phospho-ERK1/2 antibody (Cell Signaling cat#9101, dilution 1:1000)",0.95,Accept,Experimental Usage,anti-Phospho-ERK1/2 antibody (Cell Signaling cat#9101)
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"and ananti-ERK1/2 antibody (Cell Signaling cat#9102, dilution 1:1000)",0.95,Accept,Experimental Usage,anti-ERK1/2 antibody (Cell Signaling cat#9102)
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,...followed by overnight incubation in a 1:250 dilution of total c-met rabbit polyclonal antibody (Santa Cruz) or a 1:50 dilution of phosphorylated c-met...,0.9,Accept,Experimental Usage,c-met rabbit polyclonal antibody (Santa Cruz)
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"...or a 1:50 dilution of phosphorylated c-met (phosphorylated tyrosine sites pY1230, pY1234, and pY1236) rabbit polyclonal antibody (Invitrogen) at 4°C...",0.9,Accept,Experimental Usage,phosphorylated c-met rabbit polyclonal antibody (Invitrogen)
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Other slides were stained in a 1:100 dilution of Ki67 rat monoclonal antibody (Dako) following the IHC procedure described above...,0.9,Accept,Experimental Usage,Ki67 rat monoclonal antibody (Dako)
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma) or mesothelin (Santa Cruz)...,0.85,Accept,Experimental Usage,pan-cytokeratin antibody (Sigma)
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma) or mesothelin (Santa Cruz)...,0.85,Accept,Experimental Usage,cytokeratin 8 antibody (Sigma)
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma) or mesothelin (Santa Cruz)...,0.85,Accept,Experimental Usage,mesothelin antibody (Santa Cruz)
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,1 × 10 6 MM cells were incubated with or without 10 μL of anti-CD24 FITC-labeled antibody (BD Biosciences) for 30-40 min in 100 μL of PBS...,0.9,Accept,Experimental Usage,anti-CD24 FITC-labeled antibody (BD Biosciences)
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,The anti-p55 mouse monoclonal antibody was generated by immunizing BALB/c mice with the recombinant SH3-GUK segment of human erythrocyte p55 protein. The clone 2G4 was selected,0.95,Accept,Development,anti-p55 mouse monoclonal antibody (clone 2G4)
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,Another anti-merlin polyclonal antibody (A-19) was purchased from Santa Cruz Biotechnology,0.9,Accept,Experimental Usage,anti-merlin polyclonal antibody (A-19)
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,mouse anti-S100 (SIGMA); mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA); rabbit anti-NF-H (Chemicon),0.85,Accept,Experimental Usage,mouse anti-S100 (SIGMA)
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,mouse anti-S100 (SIGMA); mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA),0.85,Accept,Experimental Usage,mouse anti-GFAP (Chemicon)
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA); rabbit anti-NF-H (Chemicon),0.85,Accept,Experimental Usage,rabbit anti-GFAP (SIGMA)
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,rabbit anti-GFAP (SIGMA); rabbit anti-NF-H (Chemicon); and mouse anti-Caspr,0.85,Accept,Experimental Usage,rabbit anti-NF-H (Chemicon)
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,"and mouse anti-Caspr, kindly provided by Dr. Elior Peles, The Weizmann Institute of Science, Rehovot, Israel",0.85,Accept,Experimental Usage,mouse anti-Caspr
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"Fibroblasts were stained for 30 min at 4°C with 1 µg/ml of FITC-conjugated anti-ColIA monoclonal antibody (Pharmingen, San Diego, CA, USA)",0.85,Accept,Experimental Usage,FITC-conjugated anti-ColIA monoclonal antibody
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"TGF-β neutralizing antibodies were obtained from R&D Systems, Inc. (Cat. no. AF-101-NA) and utilized as suggested by the manufacturer",0.85,Accept,Experimental Usage,TGF-β neutralizing antibodies
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)",0.85,Accept,Experimental Usage,anti-Abl (K12)
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or anti-Flag (Sigma-Aldrich)",0.8,Accept,Experimental Usage,anti-Flag
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"All tissues were sectioned (5 µm thickness), mounted onto slides and stained with PE-conjugated anti-ColIA antibody and counterstained with DAPI",0.85,Accept,Experimental Usage,PE-conjugated anti-ColIA antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"Anti-Nestin antibody primary IF CST (Danvers, USA)",0.85,Accept,Experimental Usage,Anti-Nestin antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-SOX2 antibody primary IF CST,0.85,Accept,Experimental Usage,Anti-SOX2 antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-MAP2 antibody primary IF and WB CST,0.85,Accept,Experimental Usage,Anti-MAP2 antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-β3-Tubulin antibody primary IF and WB CST,0.85,Accept,Experimental Usage,Anti-β3-Tubulin antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-GFAP antibody primary IF and WB CST,0.85,Accept,Experimental Usage,Anti-GFAP antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-NF-200 antibody primary IF and WB CST,0.85,Accept,Experimental Usage,Anti-NF-200 antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-NeuN antibody primary IF and WB CST,0.85,Accept,Experimental Usage,Anti-NeuN antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-cleaved caspase-3 antibody primary IF and WB CST,0.85,Accept,Experimental Usage,Anti-cleaved caspase-3 antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-neurofibromin antibody primary WB CST,0.9,Accept,Experimental Usage,Anti-neurofibromin antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-P-mTOR antibody primary WB CST,0.85,Accept,Experimental Usage,Anti-P-mTOR antibody
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-Rictor antibody primary WB CST,0.85,Accept,Experimental Usage,Anti-Rictor antibody
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,"Apoptosis was determined by counting the percent of cleaved caspase-3 + cells (1∶500 dilution; Cell Signaling Technology, Beverly MA)",0.85,Accept,Experimental Usage,cleaved caspase-3 antibody
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,"Sections were treated with citrate antigen retrieval solution (10 mM, pH 6.0) and stained with pErbB2 (1∶50 dilution)",0.8,Accept,Experimental Usage,pErbB2 antibody
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"BLBP (1:2000, rabbit, a kind gift from Dr. Todd Anthony), Calbindin (1:1000, mouse, Sigma-Aldrich)",0.9,Accept,Experimental Usage,BLBP antibody
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Calbindin (1:1000, mouse, Sigma-Aldrich), GFAP (1:2000, rabbit, DAKO, Carpinteria, CA)",0.9,Accept,Experimental Usage,Calbindin antibody
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"GFAP (1:2000, rabbit, DAKO, Carpinteria, CA) and BrdU (1:1000, rat, Abcam, Cambridge, MA)",0.9,Accept,Experimental Usage,GFAP antibody
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"BrdU (1:1000, rat, Abcam, Cambridge, MA). Immunofluorescence was performed on both paraffin and frozen sections",0.9,Accept,Experimental Usage,BrdU antibody
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"NeuN (1:400, mouse, Millipore, Billerica, MA), BLBP (1:500, rabbit, a gift from Nathaniel Heintz)",0.9,Accept,Experimental Usage,NeuN antibody
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"GABARα6 (1:500, rabbit, Millipore), BrdU (1:1000, rat, Abcam), Ki-67 (1:500, mouse, BD Pharmingen)",0.9,Accept,Experimental Usage,GABARα6 antibody
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Ki-67 (1:500, mouse, BD Pharmingen), Tbr2 (1:1000, rabbit, Abcam), Calretinin (1:1000, mouse, Millipore)",0.9,Accept,Experimental Usage,Ki-67 antibody
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Tbr2 (1:1000, rabbit, Abcam), Calretinin (1:1000, mouse, Millipore), MAP2 (1:1000, mouse, Sigma-Aldrich)",0.9,Accept,Experimental Usage,Tbr2 antibody
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"p-Erk (1:200, rabbit, Cell Signaling, Beverly, MA), p-S6 (1:1000, rabbit, Cell Signaling)",0.9,Accept,Experimental Usage,p-Erk antibody
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"p-Erk (1:200, rabbit, Cell Signaling, Beverly, MA), p-S6 (1:1000, rabbit, Cell Signaling)",0.9,Accept,Experimental Usage,p-S6 antibody
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,"S100 mouse monoclonal primary antibody (Cell Signaling Technology, Danvers, USA) diluted 1:1000",0.9,Accept,Experimental Usage,S100 mouse monoclonal primary antibody
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,"secondary antibody (1:1000, Anti-Mouse IgG (H+L), F(ab')2 Fragment Alexa Fluor 488 Conjugate, Cell Signaling Technology)",0.9,Accept,Experimental Usage,"Anti-Mouse IgG (H+L), F(ab')2 Fragment Alexa Fluor 488 Conjugate"
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"The sheared chromatin was immunoprecipitated with 5 μg of anti-XBP1 antibodies (Cell Signaling Technology, Danvers, MA, USA) overnight",0.85,Accept,Experimental Usage,anti-XBP1 antibodies
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"The primary antibodies used in the study include anti-GAPDH (Proteintech Group Inc., Rosemont, IL, USA)",0.8,Accept,Experimental Usage,anti-GAPDH
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-α-tubulin (Proteintech Group Inc., Rosemont, IL, USA)",0.8,Accept,Experimental Usage,anti-α-tubulin
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-XBP1u (Abcepta, Reservoir Victoria, Australia)",0.8,Accept,Experimental Usage,anti-XBP1u
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,anti-XBP1s (Cell Signaling),0.8,Accept,Experimental Usage,anti-XBP1s
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-Parkin (Cell Signaling, Danvers, MA, USA)",0.8,Accept,Experimental Usage,anti-Parkin
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-PINK1 (Genetex, Hsinchu, Taiwan)",0.8,Accept,Experimental Usage,anti-PINK1
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-LC3B (Cell Signaling, Danvers, MA, USA)",0.8,Accept,Experimental Usage,anti-LC3B
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-GLUT1 (Proteintech Group Inc., Rosemont, IL, USA) antibodies",0.8,Accept,Experimental Usage,anti-GLUT1
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"the primary antibodies, anti-ATP5H (Thermo Fisher Scientific, Waltham, MA, USA)",0.8,Accept,Experimental Usage,anti-ATP5H
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-LC3 antibodies (Cell Signaling, Danvers, MA, USA), were added into the wells",0.8,Accept,Experimental Usage,anti-LC3 antibodies
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"proliferation marker protein Ki-67 (antigen Ki67, monoclonal mouse anti-human Ki67 antigen, clone MIB1, M7240, DAKO)",0.95,Accept,Experimental Usage,"Ki67 antibody (clone MIB1, M7240, DAKO)"
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"cyclin-dependent kinase inhibitor p21 (p21, monoclonal mouse anti-human p21 WAF1/Cip1 , M7202, DAKO)",0.95,Accept,Experimental Usage,"p21 antibody (M7202, DAKO)"
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"tumor protein p53 (p53, monoclonal mouse anti-human p53 M7001, DAKO)",0.95,Accept,Experimental Usage,"p53 antibody (M7001, DAKO)"
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"B-cell lymphoma 2 (bcl2, monoclonal mouse anti-human bcl2 oncoprotein, M887, DAKO)",0.95,Accept,Experimental Usage,"bcl2 antibody (M887, DAKO)"
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"B-cell lymphoma 6 (bcl6, monoclonal mouse anti-human bcl6 protein, M7211, DAKO)",0.95,Accept,Experimental Usage,"bcl6 antibody (M7211, DAKO)"
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"cyclin D1 (monoclonal rabbit anti-human cyclin D1, M3642, DAKO)",0.95,Accept,Experimental Usage,"cyclin D1 antibody (M3642, DAKO)"
PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,"Membranes were incubated with rabbit anti-TSC1 antibody (Cell signaling, #4906)",0.95,Accept,Experimental Usage,"anti-TSC1 antibody (Cell signaling, #4906)"
PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,"rabbit anti-p-S6 antibody (Cell Signaling, #5364)",0.95,Accept,Experimental Usage,"anti-p-S6 antibody (Cell Signaling, #5364)"
PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,rabbit anti-S6 antibody (Cell signaling #2217),0.95,Accept,Experimental Usage,anti-S6 antibody (Cell signaling #2217)
PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,mouse anti- Vinculin antibody (Sigma-aldrich V4505),0.95,Accept,Experimental Usage,anti-Vinculin antibody (Sigma-aldrich V4505)
PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,"sections were incubated with primary antibody (Ki67, Spring, M306) overnight at 4°C",0.95,Accept,Experimental Usage,"Ki67 antibody (Spring, M306)"
PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,"Immunostaining with S100 protein (rabbit polyclonal, Dako, Carpenteria, Calif, USA) and KIT (rabbit polyclonal, Dako) was performed when necessary to confirm diagnosis.",0.9,Accept,Experimental Usage,"S100 protein (rabbit polyclonal, Dako, Carpenteria, Calif, USA)"
PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,"Immunostaining with S100 protein (rabbit polyclonal, Dako, Carpenteria, Calif, USA) and KIT (rabbit polyclonal, Dako) was performed when necessary to confirm diagnosis.",0.9,Accept,Experimental Usage,"KIT (rabbit polyclonal, Dako)"
PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,"For mouse monoclonal anti-EGFR (31G7, Zymed, South San Francisco, Calif, USA, final dilution 1/10), P53 (DO-7, Novocastra, Newcastle upon Tyne, UK, final dilution 1/50)",0.95,Accept,Experimental Usage,"anti-EGFR (31G7, Zymed, South San Francisco, Calif, USA, final dilution 1/10)"
PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,"For mouse monoclonal anti-EGFR (31G7, Zymed, South San Francisco, Calif, USA, final dilution 1/10), P53 (DO-7, Novocastra, Newcastle upon Tyne, UK, final dilution 1/50)",0.95,Accept,Experimental Usage,"P53 (DO-7, Novocastra, Newcastle upon Tyne, UK, final dilution 1/50)"
PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,"and anti-Ki-67 (Mib1 Dako, final dilution 1/50), staining was revealed with LSAB kit (Dako).",0.9,Accept,Experimental Usage,"anti-Ki-67 (Mib1 Dako, final dilution 1/50)"
PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,"For anti-Survivin (12C4, Dako, final dilution 1/100) staining was revealed with CSAII (Dako), according to manufacturer's instruction.",0.95,Accept,Experimental Usage,"anti-Survivin (12C4, Dako, final dilution 1/100)"
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"membranes were probed with several different antibodies including anti-AurkA antibodies (Cell Signalling Technology Inc., #3092)",0.95,Accept,Experimental Usage,"anti-AurkA antibodies (Cell Signalling Technology Inc., #3092)"
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"anti-AurkB antibody (Cell Signalling Technology Inc., #3094)",0.95,Accept,Experimental Usage,"anti-AurkB antibody (Cell Signalling Technology Inc., #3094)"
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"anti-Histone 3 (Cell Signalling Technology Inc., #9715)",0.95,Accept,Experimental Usage,"anti-Histone 3 (Cell Signalling Technology Inc., #9715)"
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"anti-p-Histone 3 (Cell Signalling Technology Inc., #9701)",0.95,Accept,Experimental Usage,"anti-p-Histone 3 (Cell Signalling Technology Inc., #9701)"
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"anti-PARP (Cell Signalling Technology Inc., #9542)",0.95,Accept,Experimental Usage,"anti-PARP (Cell Signalling Technology Inc., #9542)"
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"stripped and re-probed with anti-β-actin antibodies (Cell Signaling Technology, Inc. #4967) as a loading control",0.95,Accept,Experimental Usage,"anti-β-actin antibodies (Cell Signaling Technology, Inc. #4967)"
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"Schwann cells were labeled with anti-S100β antibodies (Dako, Carpenteria, CA)",0.9,Accept,Experimental Usage,anti-S100β antibodies
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"expression of the HA-tagged CNP-HRAS12V transgene was detected with anti-HA antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)",0.9,Accept,Experimental Usage,anti-HA antibodies
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"incubated overnight in primary antibody; rabbit cleaved caspase-3 (1:8000, Cell Signaling, #9661)",0.95,Accept,Experimental Usage,"rabbit cleaved caspase-3 (1:8000, Cell Signaling, #9661)"
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"rabbit p-histone 3 (1:800, Cell Signaling, #9701)",0.95,Accept,Experimental Usage,"rabbit p-histone 3 (1:800, Cell Signaling, #9701)"
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,Rabbit Ki-67 (1:5000 NCL-Ki67-P; Novocastra),0.95,Accept,Experimental Usage,Rabbit Ki-67 (1:5000 NCL-Ki67-P; Novocastra)
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,"rabbit cyclinB1 (1:500, Cell Signaling, #4138)",0.95,Accept,Experimental Usage,"rabbit cyclinB1 (1:500, Cell Signaling, #4138)"
PMID:26657314,10.1371/journal.pone.0144620,Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients.,,The schwannomatosis cell lines were stained with S100B antibodies to confirm Schwann cell identity.,0.85,Accept,Experimental Usage,S100B antibodies
PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,...stained for hematoxylin and eosin (HE) or Masson's Trichrome (MT) stains. S100 immunohistochemistry was performed as detailed previously...,0.85,Accept,Experimental Usage,S100 immunohistochemistry
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,Anti-pY397 FAK (141-9) was from Life Technologies,0.95,Accept,Experimental Usage,Anti-pY397 FAK (141-9)
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,Anti-FAK (4.47) and GAPDH (clone 374) were from Millipore,0.95,Accept,Experimental Usage,Anti-FAK (4.47)
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,Anti-FAK (4.47) and GAPDH (clone 374) were from Millipore,0.95,Accept,Experimental Usage,GAPDH (clone 374)
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,anti-actin (AC-74) was from Sigma,0.95,Accept,Experimental Usage,anti-actin (AC-74)
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,"Merlin antibodies for immunoblotting (D1D8) and immunohistochemistry (NF2, A-19) were from Cell Signaling",0.95,Accept,Experimental Usage,Merlin antibodies (D1D8)
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,"Merlin antibodies for immunoblotting (D1D8) and immunohistochemistry (NF2, A-19) were from Cell Signaling and Santa Cruz Biotechnology",0.95,Accept,Experimental Usage,NF2 antibody (A-19)
PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,"Nitrocellulose membranes were probed with the indicated antibody using standard protocols (monoclonal anti-β-actin antibody (Sigma cat# AC-74, dilution 1: 5000)",0.95,Accept,Experimental Usage,monoclonal anti-β-actin antibody (Sigma cat# AC-74)
PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,"anti-Phospho-Smad1/5 antibody (Cell Signaling cat#9516S, dilution 1:1000)",0.95,Accept,Experimental Usage,anti-Phospho-Smad1/5 antibody (Cell Signaling cat#9516S)
PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,"anti-Smad1+Smad5 antibody (Abcam cat# ab75273, dilution 1:1000)",0.95,Accept,Experimental Usage,anti-Smad1+Smad5 antibody (Abcam cat# ab75273)
PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,"anti ENPP1/PC-1 (Aviva Systems Biology, cat# OAEB02445, dilution 1:500)",0.95,Accept,Experimental Usage,"anti ENPP1/PC-1 (Aviva Systems Biology, cat# OAEB02445)"
PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,"anti-ANK (Origen, cat# TA325111, dilution 1:1000)",0.95,Accept,Experimental Usage,"anti-ANK (Origen, cat# TA325111)"
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"probed with anti-NF1 (D7R7D) rabbit monoclonal (cat. no 14623, Cell Signaling Technology, 1:1000, overnight at 4°C)",0.9,Accept,Experimental Usage,anti-NF1 (D7R7D) rabbit monoclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-LAMP1 (D4O1S) mouse monoclonal (1:100, overnight at 4°C; cat. no 15665, Cell Signaling Technology)",0.9,Accept,Experimental Usage,anti-LAMP1 (D4O1S) mouse monoclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-SQSTM1/p62 (D-3) mouse monoclonal (1:500; cat. no sc-28359, Santa Cruz Biotechnology)",0.9,Accept,Experimental Usage,anti-SQSTM1/p62 (D-3) mouse monoclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-BNIP3L/Nix (D4R4B) rabbit monoclonal (1:200, overnight at 4°C; cat. no 12396, Cell Signaling Technology)",0.9,Accept,Experimental Usage,anti-BNIP3L/Nix (D4R4B) rabbit monoclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-Tom20 (FL-145) rabbit polyclonal (1:200; cat. no sc-11415, Santa Cruz Biotechnology)",0.9,Accept,Experimental Usage,anti-Tom20 (FL-145) rabbit polyclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-cleaved caspase 3 (Asp175) rabbit polyclonal (1:200; cat. no 9661, Cell Signaling Technology)",0.9,Accept,Experimental Usage,anti-cleaved caspase 3 (Asp175) rabbit polyclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"Alexa Fluor 488 pre-conjugated anti-γ-H2AX (N1-431) mouse monoclonal (1:50 for 30 min; cat. no 560445, BD Biosciences)",0.9,Accept,Experimental Usage,Alexa Fluor 488 pre-conjugated anti-γ-H2AX (N1-431) mouse monoclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-8-hydroxyguanosine goat polyclonal (1:200; cat. no DR1001, Millipore)",0.9,Accept,Experimental Usage,anti-8-hydroxyguanosine goat polyclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-FLAG (M2) mouse monoclonal (1:500 for 2 h at 37°C; cat. no F1804, Sigma-Aldrich)",0.9,Accept,Experimental Usage,anti-FLAG (M2) mouse monoclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-PARP (46D11) rabbit monoclonal (cat. no 9532, Cell Signaling Technology, 1:5000, overnight at 4°C)",0.9,Accept,Experimental Usage,anti-PARP (46D11) rabbit monoclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-LC3BI/II rabbit polyclonal (cat. no #2775, Cell Signaling, 1:1000, overnight at 4°C)",0.9,Accept,Experimental Usage,anti-LC3BI/II rabbit polyclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-C17orf59/BORCS6 rabbit polyclonal (cat. no PA566346, Invitrogen, 1:1000, overnight at 4°C)",0.9,Accept,Experimental Usage,anti-C17orf59/BORCS6 rabbit polyclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-GAPDH (14C10) rabbit monoclonal (cat. no 2118, Cell Signaling Technology, 1:2500, 1 h at RT)",0.9,Accept,Experimental Usage,anti-GAPDH (14C10) rabbit monoclonal
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,"anti-α-tubulin (B-1-2-5) mouse monoclonal (cat. no sc-23948, Santa Cruz Biotehcnology, 1:10,000, 1 h at RT)",0.9,Accept,Experimental Usage,anti-α-tubulin (B-1-2-5) mouse monoclonal
PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,"sections were incubated overnight with rabbit anti-Iba1 (1:3000; Wako, Richmond, VA), mouse anti-Ki67 (1:500; BD Biosciences, San Jose, CA)",0.95,Accept,Experimental Usage,"rabbit anti-Iba1 (1:3000; Wako, Richmond, VA)"
PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,"rabbit anti-Iba1 (1:3000; Wako, Richmond, VA), mouse anti-Ki67 (1:500; BD Biosciences, San Jose, CA), or rat anti-CD34 (1:50; BD Biosciences)",0.95,Accept,Experimental Usage,"mouse anti-Ki67 (1:500; BD Biosciences, San Jose, CA)"
PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,"mouse anti-Ki67 (1:500; BD Biosciences, San Jose, CA), or rat anti-CD34 (1:50; BD Biosciences) followed by incubation with biotinylated secondary antibodies",0.95,Accept,Experimental Usage,rat anti-CD34 (1:50; BD Biosciences)
PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,"incubated overnight at 4°C with rabbit anti-Iba1 (1:2000), rat anti-CD11b (M1/70, 1:10; BD Biosciences), or mouse anti-Ki67 (1:500; BD Biosciences)",0.95,Accept,Experimental Usage,"rat anti-CD11b (M1/70, 1:10; BD Biosciences)"
PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,"cell surface staining was performed with anti-CD45-APC (30-F11, BD Biosciences) and anti-CD11b-PerCP-Cy5.5 antibodies",0.95,Accept,Experimental Usage,"anti-CD45-APC (30-F11, BD Biosciences)"
PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,"cell surface staining was performed with anti-CD45-APC (30-F11, BD Biosciences) and anti-CD11b-PerCP-Cy5.5 antibodies",0.9,Accept,Experimental Usage,anti-CD11b-PerCP-Cy5.5
PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,"then stained with CD68-R-PE (FA-11, AbD Serotec, Oxford, UK) or rabbit anti-Iba1 (Wako) conjugated to R-PE using the Zenon Rabbit IgG Labeling Kit",0.95,Accept,Experimental Usage,"CD68-R-PE (FA-11, AbD Serotec, Oxford, UK)"
PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,"After Fc blocking with a CD16/32 antibody (BD Biosciences), cell surface staining was performed with anti-CD45-APC",0.9,Accept,Experimental Usage,CD16/32 antibody (BD Biosciences)
PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,The primary antibodies used were against NF1 (1:300; Santa Cruz Biotechnology); phospho-ERK p42/p44 and total ERK p42/p44,0.9,Accept,Experimental Usage,NF1 antibody (Santa Cruz Biotechnology)
PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,"phospho-ERK p42/p44 and total ERK p42/p44 (1:1,000; NEB); β-actin (1:5,000; Sigma)",0.9,Accept,Experimental Usage,phospho-ERK p42/p44 antibody (NEB)
PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,"phospho-ERK p42/p44 and total ERK p42/p44 (1:1,000; NEB); β-actin (1:5,000; Sigma)",0.9,Accept,Experimental Usage,total ERK p42/p44 antibody (NEB)
PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,"phospho-ERK p42/p44 and total ERK p42/p44 (1:1,000; NEB); β-actin (1:5,000; Sigma); synapsin I (1:1000; NEB)",0.9,Accept,Experimental Usage,β-actin antibody (Sigma)
PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,"β-actin (1:5,000; Sigma); synapsin I (1:1000; NEB); phospho-synapsin I is a gift from P. Greengard",0.9,Accept,Experimental Usage,synapsin I antibody (NEB)
PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,"synapsin I (1:1000; NEB); phospho-synapsin I is a gift from P. Greengard (Rockefeller University, New York, NY)",0.85,Accept,Experimental Usage,phospho-synapsin I antibody (P. Greengard)
PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,"The primary antibodies used were against phospho-Thr202/Tyr204 ERK p42/p44 (New England Biolabs), GAD65/67 (Chemicon)",0.9,Accept,Experimental Usage,phospho-Thr202/Tyr204 ERK p42/p44 antibody (New England Biolabs)
PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,"The primary antibodies used were against phospho-Thr202/Tyr204 ERK p42/p44 (New England Biolabs), GAD65/67 (Chemicon)",0.9,Accept,Experimental Usage,GAD65/67 antibody (Chemicon)
PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,"incubated overnight at 4°C with antibodies recognizing mesothelin (dilution 1:2,000; Santa Cruz Biotechnology, Santa Cruz, CA, clone B-3)",0.95,Accept,Experimental Usage,"anti-mesothelin (Santa Cruz Biotechnology, clone B-3)"
PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,"SV40 large T-antigen (1:2000; Santa Cruz Biotechnology, Pab101), and β-actin (1:20,000; Sigma-Aldrich, clone ac-74)",0.95,Accept,Experimental Usage,"anti-SV40 large T-antigen (Santa Cruz Biotechnology, Pab101)"
PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,"and β-actin (1:20,000; Sigma-Aldrich, clone ac-74). Secondary biotinylated antibodies were used at a dilution of 1:20,000",0.95,Accept,Experimental Usage,"anti-β-actin (Sigma-Aldrich, clone ac-74)"
PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,"Primary antibodies used were anti-wide spectrum cytokeratin and anti-vimentin (Abcam Ab9377, 1:100 and Ab92547, 1:500, respectively).",0.95,Accept,Experimental Usage,anti-wide spectrum cytokeratin (Abcam Ab9377)
PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,"Primary antibodies used were anti-wide spectrum cytokeratin and anti-vimentin (Abcam Ab9377, 1:100 and Ab92547, 1:500, respectively).",0.95,Accept,Experimental Usage,anti-vimentin (Abcam Ab92547)
PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,"mouse monoclonal anti-pan-cytokeratin, clone Lu-5 (BMA Biomedicals, Augst, Switzerland, T-1302; 1:500), or rabbit polyclonal anti-desmin",0.95,Accept,Experimental Usage,"anti-pan-cytokeratin, clone Lu-5 (BMA Biomedicals, T-1302)"
PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,"or rabbit polyclonal anti-desmin (Sigma D8281; 1:500). After washing, the cell-containing coverslips were incubated with secondary antibodies",0.95,Accept,Experimental Usage,anti-desmin (Sigma D8281)
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,"Cells were incubated with α-tubulin (Invitrogen, 1:1000) and NGFR (Advance Targeting systems, 1:100) antibodies",0.85,Accept,Experimental Usage,"α-tubulin (Invitrogen, 1:1000)"
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,"Cells were incubated with α-tubulin (Invitrogen, 1:1000) and NGFR (Advance Targeting systems, 1:100) antibodies",0.85,Accept,Experimental Usage,"NGFR (Advance Targeting systems, 1:100)"
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,All antibodies used were diluted in 3% non-fat dry milk and include P-ERK 1/2 (Cell Signalling diluted 1:2000),0.85,Accept,Experimental Usage,P-ERK 1/2 (Cell Signalling diluted 1:2000)
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,"ERK 1/2 (Millipore diluted 1:1000), P-PKA α/β (Invitrogen diluted 1ug/ml)",0.85,Accept,Experimental Usage,ERK 1/2 (Millipore diluted 1:1000)
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,"ERK 1/2 (Millipore diluted 1:1000), P-PKA α/β (Invitrogen diluted 1ug/ml), PKA α/β",0.85,Accept,Experimental Usage,P-PKA α/β (Invitrogen diluted 1ug/ml)
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,"P-PKA α/β (Invitrogen diluted 1ug/ml), PKA α/β (Termo Fisher Scientific diluted 1:500) NF1 c-terminal",0.85,Accept,Experimental Usage,PKA α/β (Termo Fisher Scientific diluted 1:500)
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,"PKA α/β (Termo Fisher Scientific diluted 1:500) NF1 c-terminal (Bethyl diluted 1:1000), NF1 n-terminal",0.9,Accept,Experimental Usage,NF1 c-terminal (Bethyl diluted 1:1000)
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,"NF1 c-terminal (Bethyl diluted 1:1000), NF1 n-terminal (Santa Cruz diluted 1:500) and α-Tubulin",0.9,Accept,Experimental Usage,NF1 n-terminal (Santa Cruz diluted 1:500)
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,NF1 n-terminal (Santa Cruz diluted 1:500) and α-Tubulin (Sigma Aldrich 1:1000),0.85,Accept,Experimental Usage,α-Tubulin (Sigma Aldrich 1:1000)
PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,"Anti-v5 epitope (Invitrogen), anti-merlin (Santa Cruz), anti–mammalian sterile 20-like 1/2 (MST1/2; Bethyl Laboratories)",0.85,Accept,Experimental Usage,anti-v5 epitope (Invitrogen)
PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,"Anti-v5 epitope (Invitrogen), anti-merlin (Santa Cruz), anti–mammalian sterile 20-like 1/2 (MST1/2; Bethyl Laboratories)",0.85,Accept,Experimental Usage,anti-merlin (Santa Cruz)
PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,"anti-merlin (Santa Cruz), anti–mammalian sterile 20-like 1/2 (MST1/2; Bethyl Laboratories), anti-Lats2 (Bethyl Laboratories)",0.85,Accept,Experimental Usage,anti–mammalian sterile 20-like 1/2 (MST1/2; Bethyl Laboratories)
PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,"anti–mammalian sterile 20-like 1/2 (MST1/2; Bethyl Laboratories), anti-Lats2 (Bethyl Laboratories), anti–Yes-associated protein (YAP; Abnova)",0.85,Accept,Experimental Usage,anti-Lats2 (Bethyl Laboratories)
PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,"anti-Lats2 (Bethyl Laboratories), anti–Yes-associated protein (YAP; Abnova), anti–cellular inhibitor of apoptosis 1/2 (cIAP1/2; Santa Cruz)",0.85,Accept,Experimental Usage,anti–Yes-associated protein (YAP; Abnova)
PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,"anti–Yes-associated protein (YAP; Abnova), anti–cellular inhibitor of apoptosis 1/2 (cIAP1/2; Santa Cruz), anti-actin (Sigma)",0.85,Accept,Experimental Usage,anti–cellular inhibitor of apoptosis 1/2 (cIAP1/2; Santa Cruz)
PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,"anti–cellular inhibitor of apoptosis 1/2 (cIAP1/2; Santa Cruz), anti-actin (Sigma), anti–phosphorylated MST1/2 (Cell Signaling)",0.85,Accept,Experimental Usage,anti-actin (Sigma)
PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,"anti-actin (Sigma), anti–phosphorylated MST1/2 (Cell Signaling), anti–phosphorylated Lats2 (Abnova)",0.85,Accept,Experimental Usage,anti–phosphorylated MST1/2 (Cell Signaling)
PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,"anti–phosphorylated MST1/2 (Cell Signaling), anti–phosphorylated Lats2 (Abnova), and anti–phosphorylated YAP (Cell Signaling)",0.85,Accept,Experimental Usage,anti–phosphorylated Lats2 (Abnova)
PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,"anti–phosphorylated Lats2 (Abnova), and anti–phosphorylated YAP (Cell Signaling) were used in the experiments",0.85,Accept,Experimental Usage,anti–phosphorylated YAP (Cell Signaling)
PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,"...The following antibodies were used to classify the tumors: S100 (1:4000; Agilent Dako, Santa Clara, CA, USA; GA50461-2)...",0.95,Accept,Experimental Usage,"S100 antibody (1:4000; Agilent Dako, Santa Clara, CA, USA; GA50461-2)"
PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,"...CD34 (1:400; Bioss, Woburn, MA, USA; bs-8996R)...",0.95,Accept,Experimental Usage,"CD34 antibody (1:400; Bioss, Woburn, MA, USA; bs-8996R)"
PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,"...Sox10 (1:100; Abcam, Cambridge, UK; ab227680)...",0.95,Accept,Experimental Usage,"Sox10 antibody (1:100; Abcam, Cambridge, UK; ab227680)"
PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,"...CD117 (1:100, Cell Signaling; 37805S)...",0.95,Accept,Experimental Usage,"CD117 antibody (1:100, Cell Signaling; 37805S)"
PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,"...GFAP (1:200, Abcam; ab16997)...",0.95,Accept,Experimental Usage,"GFAP antibody (1:200, Abcam; ab16997)"
PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,"...AIF1 (1:500, LSBio; LS-B2645)...",0.95,Accept,Experimental Usage,"AIF1 antibody (1:500, LSBio; LS-B2645)"
PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,"...SMA (1:250, LSBio; LS-B3933)...",0.95,Accept,Experimental Usage,"SMA antibody (1:250, LSBio; LS-B3933)"
PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,"incubated with primary antibodies [rabbit anti-SMA (Novus, NB600-531); rabbit anti-COL11A1 (ThermoScientific; PA5-68410)",0.95,Accept,Experimental Usage,"rabbit anti-SMA (Novus, NB600-531)"
PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,"rabbit anti-SMA (Novus, NB600-531); rabbit anti-COL11A1 (ThermoScientific; PA5-68410); rabbit anti-FAP (Abcam; ab53066)",0.95,Accept,Experimental Usage,rabbit anti-COL11A1 (ThermoScientific; PA5-68410)
PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,rabbit anti-COL11A1 (ThermoScientific; PA5-68410); rabbit anti-FAP (Abcam; ab53066); rabbit anti-collagen VI (Abcam; ab6588),0.95,Accept,Experimental Usage,rabbit anti-FAP (Abcam; ab53066)
PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,rabbit anti-FAP (Abcam; ab53066); rabbit anti-collagen VI (Abcam; ab6588)] diluted in 3% donkey serum,0.95,Accept,Experimental Usage,rabbit anti-collagen VI (Abcam; ab6588)
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"Blbp (Millipore, ABN14; rabbit, 1:500)",0.9,Accept,Experimental Usage,"Blbp antibody (Millipore, ABN14)"
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"BrdU (Abcam, ab6326; rat, 1:100)",0.9,Accept,Experimental Usage,"BrdU antibody (Abcam, ab6326)"
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"Isl1/2 (Developmental Studies Hybridoma Bank, Clone # 39.4D5; mouse, 1:500)",0.9,Accept,Experimental Usage,Isl1/2 antibody (Clone # 39.4D5)
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"Ki67 (Vector Laboratories, VP-RM04; rabbit, 1:250)",0.9,Accept,Experimental Usage,"Ki67 antibody (Vector Laboratories, VP-RM04)"
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"Nf2 (Sigma, HPA003097; rabbit, 1:1000 and amplification with Invitrogen TSA kit)",0.95,Accept,Experimental Usage,"Nf2 antibody (Sigma, HPA003097)"
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"p75 (Promega, G3231; rabbit, 1:2000)",0.9,Accept,Experimental Usage,"p75 antibody (Promega, G3231)"
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"S100β (Sigma, S2532; mouse, 1:100 and amplification with Invitrogen TSA kit)",0.9,Accept,Experimental Usage,"S100β antibody (Sigma, S2532)"
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"Sox10 (Santa Cruz, sc-17342; goat, 1:250)",0.9,Accept,Experimental Usage,"Sox10 antibody (Santa Cruz, sc-17342)"
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"TrkA (provided by Louis Reichardt, University of California, San Francisco, CA; rabbit, 1:1000)",0.85,Accept,Experimental Usage,TrkA antibody
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"Tuj1 (Covance, MMS-435P; mouse, 1:1000)",0.9,Accept,Experimental Usage,"Tuj1 antibody (Covance, MMS-435P)"
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"Yap/Taz (Cell Signaling, 8418; rabbit, 1:200 and amplification with Invitrogen TSA kit)",0.9,Accept,Experimental Usage,"Yap/Taz antibody (Cell Signaling, 8418)"
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"pYap (Cell Signaling, 4911; rabbit, 1:200)",0.9,Accept,Experimental Usage,"pYap antibody (Cell Signaling, 4911)"
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,"GAPDH (Sigma, G8795, mouse; 1:10,000)",0.9,Accept,Experimental Usage,"GAPDH antibody (Sigma, G8795)"
PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,"The following antibodies were used: pERK (Cell Signaling Technologies, #4370, 1:1,000 dilution)",0.95,Accept,Experimental Usage,"pERK (Cell Signaling Technologies, #4370)"
PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,"total ERK (Cell Signaling Technologies, #4695, 1:1,000 dilution)",0.95,Accept,Experimental Usage,"total ERK (Cell Signaling Technologies, #4695)"
PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,"pAKT (Cell Signaling Technologies, #4060, 1:1,000 dilution)",0.95,Accept,Experimental Usage,"pAKT (Cell Signaling Technologies, #4060)"
PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,"total AKT (Cell Signaling Technologies, # 4685, 1:1,000 dilution)",0.95,Accept,Experimental Usage,"total AKT (Cell Signaling Technologies, #4685)"
PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,"pMEK (Cell Signaling Technologies, #9121, 1:1,000 dilution)",0.95,Accept,Experimental Usage,"pMEK (Cell Signaling Technologies, #9121)"
PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,"total MEK (Cell Signaling Technologies, #8727, 1:1,000 dilution)",0.95,Accept,Experimental Usage,"total MEK (Cell Signaling Technologies, #8727)"
PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,"neurofibromin (Millipore, #3668175, 1:1000 dilution)",0.95,Accept,Experimental Usage,"neurofibromin (Millipore, #3668175)"
PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,"SHP2 (Cell Signaling Technologies, #3397, 1:1,000 dilution)",0.95,Accept,Experimental Usage,"SHP2 (Cell Signaling Technologies, #3397)"
PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,"SOS2 (Santa Cruz, sc-393667)",0.95,Accept,Experimental Usage,"SOS2 (Santa Cruz, sc-393667)"
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,"The samples were then incubated with polyclonal rabbit anti-PGP 9.5 (Dako #Z5116, Glostrup, Denmark, antibody dilution 1:200)",0.9,Accept,Experimental Usage,polyclonal rabbit anti-PGP 9.5
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,"Bound antibody was visualized with anti-rabbit secondary antibody (Histofine Max PO Multi, #414152 F, Nichirei Biosciences Inc., Tokyo, Japan)",0.85,Accept,Experimental Usage,Histofine Max PO Multi
PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,"β-TubulinIII (rabbit, 1:2000, Sigma)",0.9,Accept,Experimental Usage,β-TubulinIII antibody
PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,"GAP43 (rabbit, 1:1000, Abcam)",0.9,Accept,Experimental Usage,GAP43 antibody
PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,"GFAP (rabbit, 1:2000, DAKO)",0.9,Accept,Experimental Usage,GFAP antibody
PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,"nestin (mouse, 1:200, Chemicon)",0.9,Accept,Experimental Usage,nestin antibody
PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,"S100β(rabbit, 1:5000, DAKO)",0.9,Accept,Experimental Usage,S100β antibody
PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,Western blotting on lysates of SKPs and 3T3 cells with Dhh antibody (Santa Cruz Biotechnology),0.9,Accept,Experimental Usage,Dhh antibody
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,"Primary antibodies were: goat anti-EGFR (Santa Cruz, SC-03-G, 1:10)",0.9,Accept,Experimental Usage,"goat anti-EGFR (Santa Cruz, SC-03-G)"
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,rabbit anti-P75 (Chemicon 1:400),0.85,Accept,Experimental Usage,rabbit anti-P75 (Chemicon)
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,mouse anti-β-Tubulin (Chemicon 1:200),0.85,Accept,Experimental Usage,mouse anti-β-Tubulin (Chemicon)
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,rabbit anti-S100β (DAKO 1:2000),0.85,Accept,Experimental Usage,rabbit anti-S100β (DAKO)
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,mouse anti-SMA (Sigma 1:500),0.85,Accept,Experimental Usage,mouse anti-SMA (Sigma)
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,"rabbit anti-NF-M (Chemicon, 1:200)",0.85,Accept,Experimental Usage,rabbit anti-NF-M (Chemicon)
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,"mouse anti-human monoclonal antibodies against CD34 (8G12/HPCA-2, Becton-Dickinson; San Jose, CA) bound to allophycocyanin",0.9,Accept,Experimental Usage,"CD34 (8G12/HPCA-2, Becton-Dickinson)"
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,"p75/NGFR (C40–1457, Becton-Dickinson) bound to phycoerythrin (PE)",0.9,Accept,Experimental Usage,"p75/NGFR (C40–1457, Becton-Dickinson)"
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,"EGFR (EGFR1, Research Diagnostics Inc; Flanders, NJ) bound to FITC",0.9,Accept,Experimental Usage,"EGFR (EGFR1, Research Diagnostics Inc)"
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,anti-CD16/CD32 antibody (Becton-Dickinson) to block Fc gamma receptor unspecific binding,0.85,Accept,Experimental Usage,anti-CD16/CD32 antibody (Becton-Dickinson)
PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,"The following primary antibodies were used in the immunohistochemistry studies: S100 (Agilent Technologies, GA-50461-2)",0.95,Accept,Experimental Usage,"S100 antibody (Agilent Technologies, GA-50461-2)"
PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,"desmin (abcam, ab15200)",0.95,Accept,Experimental Usage,"desmin antibody (abcam, ab15200)"
PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,"SMA (GeneTex, GTX100034)",0.95,Accept,Experimental Usage,"SMA antibody (GeneTex, GTX100034)"
PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,"Nf1 (Santa Cruz, sc-376886)",0.95,Accept,Experimental Usage,"Nf1 antibody (Santa Cruz, sc-376886)"
PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,"p53 (Santa Cruz, sc-126)",0.95,Accept,Experimental Usage,"p53 antibody (Santa Cruz, sc-126)"
PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,"Iba1 (Fujifilm, 019–19741)",0.95,Accept,Experimental Usage,"Iba1 antibody (Fujifilm, 019–19741)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"Cell suspensions were stained with 1:100 dilutions of Phycoerythrin-conjugated anti-human HLA-A/B/C antibody (W6/32) (eBioscience, catalog number 12-9983-42)",0.9,Accept,Experimental Usage,"Phycoerythrin-conjugated anti-human HLA-A/B/C antibody (W6/32) (eBioscience, catalog number 12-9983-42)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"Phycoerythrin-conjugated anti-human β-2-microglobulin antibody (2M2) (Biolegend, catalog number 316306)",0.9,Accept,Experimental Usage,"Phycoerythrin-conjugated anti-human β-2-microglobulin antibody (2M2) (Biolegend, catalog number 316306)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"Phycoerythrin -Cyanine 7-conjugated anti-human PD-L1 antibody (29E.2A3) (Biolegend, catalog number 329717)",0.9,Accept,Experimental Usage,"Phycoerythrin-Cyanine 7-conjugated anti-human PD-L1 antibody (29E.2A3) (Biolegend, catalog number 329717)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"Allophycocyanin-conjugated anti-human CTLA-4 antibody (L3D10) (Biolegend, catalog number 349907)",0.9,Accept,Experimental Usage,"Allophycocyanin-conjugated anti-human CTLA-4 antibody (L3D10) (Biolegend, catalog number 349907)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"An antibody to HLA Class 1 ABC (clone EMR8-5, Abcam Inc, catalog number ab70328) was used at a dilution factor of 1:6000",0.9,Accept,Experimental Usage,"HLA Class 1 ABC antibody (clone EMR8-5, Abcam Inc, catalog number ab70328)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"β-2-Microglobulin antibody (HPA006361, rabbit polyclonal, Sigma-Aldrich, catalog number HPA006361) was used at a dilution of 1:6000",0.9,Accept,Experimental Usage,"β-2-Microglobulin antibody (HPA006361, rabbit polyclonal, Sigma-Aldrich, catalog number HPA006361)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"An antibody to PD-L1 (clone B55, Sino Biological Inc., catalog number 10084-H08H) was used at a dilution factor of 1:200",0.9,Accept,Experimental Usage,"PD-L1 antibody (clone B55, Sino Biological Inc., catalog number 10084-H08H)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"Antibodies to CD4 (clone SP35, Cell Marque, catalog number 104R-18) and CD8 (clone 4B11, Leica Microsystems, catalog number PA0183) were used pre-diluted",0.9,Accept,Experimental Usage,"CD4 antibody (clone SP35, Cell Marque, catalog number 104R-18)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"Antibodies to CD4 (clone SP35, Cell Marque, catalog number 104R-18) and CD8 (clone 4B11, Leica Microsystems, catalog number PA0183) were used pre-diluted",0.9,Accept,Experimental Usage,"CD8 antibody (clone 4B11, Leica Microsystems, catalog number PA0183)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"Antibodies to CD56 (clone 1B6, Leica Microsystems, catalog number NCL-L-CD56-1B6) and CD45RO (clone UCHL1, Leica Microsystems, catalog number PA0146) were used pre-diluted",0.9,Accept,Experimental Usage,"CD56 antibody (clone 1B6, Leica Microsystems, catalog number NCL-L-CD56-1B6)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"Antibodies to CD56 (clone 1B6, Leica Microsystems, catalog number NCL-L-CD56-1B6) and CD45RO (clone UCHL1, Leica Microsystems, catalog number PA0146) were used pre-diluted",0.9,Accept,Experimental Usage,"CD45RO antibody (clone UCHL1, Leica Microsystems, catalog number PA0146)"
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,"An antibody to FOXP3 (clone 236A/E7, Abcam Inc., catalog number ab20034) was used at a dilution factor of 1:100",0.9,Accept,Experimental Usage,"FOXP3 antibody (clone 236A/E7, Abcam Inc., catalog number ab20034)"
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,"Primary antibody conditions were diluted in IF buffer and used as follows: anti-Tom20 FL-145 (Santa Cruz, 1:200, RT, 1 hour)",0.9,Accept,Experimental Usage,anti-Tom20 FL-145 (Santa Cruz)
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,"anti-Tid1 Ab-2 RS13 (Neomarkers, 1:200 4°C, overnight), anti-p-H2AX Ser139-488 N1-431 (BD, 1:100, 4°C, 30 minutes, no secondary)",0.9,Accept,Experimental Usage,anti-Tid1 Ab-2 RS13 (Neomarkers)
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,"anti-Tid1 Ab-2 RS13 (Neomarkers, 1:200 4°C, overnight), anti-p-H2AX Ser139-488 N1-431 (BD, 1:100, 4°C, 30 minutes, no secondary)",0.9,Accept,Experimental Usage,anti-p-H2AX Ser139-488 N1-431 (BD)
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,"blocked with 5% nonfat dry milk in TBST and probed with anti-LC3BI/II #2775 (Cell Signaling, 1:1000, overnight)",0.9,Accept,Experimental Usage,anti-LC3BI/II #2775 (Cell Signaling)
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,"anti-p62/SQSTM-1 D-3 (Santa Cruz, 1:1000, 1 h), anti-alpha-tubulin B-1-2-5 (Santa Cruz, 1:10000, 1 h)",0.9,Accept,Experimental Usage,anti-p62/SQSTM-1 D-3 (Santa Cruz)
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,"anti-p62/SQSTM-1 D-3 (Santa Cruz, 1:1000, 1 h), anti-alpha-tubulin B-1-2-5 (Santa Cruz, 1:10000, 1 h)",0.9,Accept,Experimental Usage,anti-alpha-tubulin B-1-2-5 (Santa Cruz)
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,"anti-K63 polyubiquitin #5921 (Cell Signaling, 1:1000, 1 h), anti-pK48 polyubiquitin #8081 (Cell Signaling, 1:2000, 1 h)",0.9,Accept,Experimental Usage,anti-K63 polyubiquitin #5921 (Cell Signaling)
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,"anti-K63 polyubiquitin #5921 (Cell Signaling, 1:1000, 1 h), anti-pK48 polyubiquitin #8081 (Cell Signaling, 1:2000, 1 h)",0.9,Accept,Experimental Usage,anti-pK48 polyubiquitin #8081 (Cell Signaling)
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,"anti-GAPDH ab9485-100 (Abcam, 1:1000, overnight), anti-RIP (BD Transduction Laboratories, 1:1000, overnight)",0.9,Accept,Experimental Usage,anti-GAPDH ab9485-100 (Abcam)
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,"anti-GAPDH ab9485-100 (Abcam, 1:1000, overnight), anti-RIP (BD Transduction Laboratories, 1:1000, overnight)",0.9,Accept,Experimental Usage,anti-RIP (BD Transduction Laboratories)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"Antibodies recognizing phospho-Erk 1/2 (#9101), Erk2 (#9108), Akt phosphorylated at Ser473 (#9271), Akt (#9272), SAPK/JNK phosphorylated on Thr183/Tyr185 (#9251)",0.9,Accept,Experimental Usage,anti-phospho-Erk 1/2 (#9101)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"Antibodies recognizing phospho-Erk 1/2 (#9101), Erk2 (#9108), Akt phosphorylated at Ser473 (#9271), Akt (#9272)",0.9,Accept,Experimental Usage,anti-Erk2 (#9108)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"Antibodies recognizing phospho-Erk 1/2 (#9101), Erk2 (#9108), Akt phosphorylated at Ser473 (#9271), Akt (#9272)",0.9,Accept,Experimental Usage,anti-Akt phosphorylated at Ser473 (#9271)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"Akt phosphorylated at Ser473 (#9271), Akt (#9272), SAPK/JNK phosphorylated on Thr183/Tyr185 (#9251), SAPK/JNK (#9252)",0.9,Accept,Experimental Usage,anti-Akt (#9272)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"Akt (#9272), SAPK/JNK phosphorylated on Thr183/Tyr185 (#9251), SAPK/JNK (#9252) or Src family members phosphorylated at Tyr416 (#2101)",0.9,Accept,Experimental Usage,anti-SAPK/JNK phosphorylated on Thr183/Tyr185 (#9251)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"SAPK/JNK phosphorylated on Thr183/Tyr185 (#9251), SAPK/JNK (#9252) or Src family members phosphorylated at Tyr416 (#2101)",0.9,Accept,Experimental Usage,anti-SAPK/JNK (#9252)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,SAPK/JNK (#9252) or Src family members phosphorylated at Tyr416 (#2101) or Tyr527 (#2105) were from Cell Signaling Technology,0.9,Accept,Experimental Usage,anti-Src family members phosphorylated at Tyr416 (#2101)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,Src family members phosphorylated at Tyr416 (#2101) or Tyr527 (#2105) were from Cell Signaling Technology,0.9,Accept,Experimental Usage,anti-Src family members phosphorylated at Tyr527 (#2105)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"Rabbit polyclonal antibodies recognizing FAK (sc-932), erbB2 (sc-284), erbB4 (sc-283) and NRG-1 transmembrane precursors",0.9,Accept,Experimental Usage,anti-FAK (sc-932)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"Rabbit polyclonal antibodies recognizing FAK (sc-932), erbB2 (sc-284), erbB4 (sc-283) and NRG-1 transmembrane precursors",0.9,Accept,Experimental Usage,anti-erbB2 (sc-284)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"Rabbit polyclonal antibodies recognizing FAK (sc-932), erbB2 (sc-284), erbB4 (sc-283) and NRG-1 transmembrane precursors",0.9,Accept,Experimental Usage,anti-erbB4 (sc-283)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"erbB4 (sc-283) and NRG-1 transmembrane precursors with an ""a"" variant carboxy terminus (sc-348) and a goat polyclonal anti-β 1 integrin (sc-6622)",0.9,Accept,Experimental Usage,anti-NRG-1 transmembrane precursors (sc-348)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,"NRG-1 transmembrane precursors with an ""a"" variant carboxy terminus (sc-348) and a goat polyclonal anti-β 1 integrin (sc-6622) antibody",0.9,Accept,Experimental Usage,anti-β1 integrin (sc-6622)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,Mouse monoclonal antibodies recognizing erbB3 (clone RTJ.1; #554208) or erbB4 (HFR1; sc-53280) were from BD PharMingen,0.9,Accept,Experimental Usage,anti-erbB3 (clone RTJ.1; #554208)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,Mouse monoclonal antibodies recognizing erbB3 (clone RTJ.1; #554208) or erbB4 (HFR1; sc-53280) were from BD PharMingen,0.9,Accept,Experimental Usage,anti-erbB4 (HFR1; sc-53280)
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,Anti-GAPDH monoclonal antibody (clone 6C5) was purchased from Fitzgerald Antibodies and Antigens,0.9,Accept,Experimental Usage,Anti-GAPDH monoclonal antibody (clone 6C5)
PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,"rabbit polyclonal antibodies of Mdm2 (Anaspec, , Fremont, CA, USA, 55470, 1:200; Blocking peptide 55470P)",0.9,Accept,Experimental Usage,"Mdm2 antibody (Anaspec, 55470)"
PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,"Pax2 (Covance, Nashville, TN, USA, PRB-276P, 1:1000)",0.9,Accept,Experimental Usage,"Pax2 antibody (Covance, PRB-276P)"
PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,"S100 (Dako, Glostrup, Denmark, Z0311, 1:2000)",0.9,Accept,Experimental Usage,"S100 antibody (Dako, Z0311)"
PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,"Sox2 (Millipore, Billerica, MA, USA, AB5603, 1:500)",0.9,Accept,Experimental Usage,"Sox2 antibody (Millipore, AB5603)"
PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,"GFAP (Dako, Z0034, 1:1000)",0.9,Accept,Experimental Usage,"GFAP antibody (Dako, Z0034)"
PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,"BLBP (Millipore, ABN14, 1:200)",0.9,Accept,Experimental Usage,"BLBP antibody (Millipore, ABN14)"
PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,"phospho-Histone 3 (Ser10) (Cell Signaling, 9701, 1:100)",0.9,Accept,Experimental Usage,"phospho-Histone 3 antibody (Cell Signaling, 9701)"
PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,"active Caspase 3 (Cell Signaling, 9661, 1:200)",0.9,Accept,Experimental Usage,"active Caspase 3 antibody (Cell Signaling, 9661)"
PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,"mouse monoclonal antibodies of GFAP (Sigma, St Louis, MO, USA, G6171, 1:400)",0.9,Accept,Experimental Usage,"GFAP antibody (Sigma, G6171)"
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"F4/80: #70076, Cell Signaling Technology (1:100)",0.9,Accept,Experimental Usage,F4/80 antibody
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"IL-6: #bs0782R, Bioss (1:100)",0.9,Accept,Experimental Usage,IL-6 antibody
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"MET: #ab216574 or #ab51067, Abcam (1:100)",0.9,Accept,Experimental Usage,MET antibody
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"SOX10: #ab180862, Abcam (1:100)",0.9,Accept,Experimental Usage,SOX10 antibody
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"NLRP3: #CAB12694, Assay Genie (1:1000 dilution)",0.9,Accept,Experimental Usage,NLRP3 antibody
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"CD68, Cell Signaling Technology (1:100)",0.9,Accept,Experimental Usage,CD68 antibody
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"pERK (#9101, Cell Signaling Technology)",0.9,Accept,Experimental Usage,pERK antibody
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"total ERK (#9102, Cell Signaling Technology)",0.9,Accept,Experimental Usage,total ERK antibody
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"phosphorylated FAK Y397 (pFAK 397, #700255, Invitrogen)",0.9,Accept,Experimental Usage,phosphorylated FAK Y397 antibody
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"vinculin (#CP74, MilliporeSigma)",0.9,Accept,Experimental Usage,vinculin antibody
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,"The following primary antibodies were used: rabbit anti-GFP 1:1,000 (Molecular Probes A-11122)",0.95,Accept,Experimental Usage,"rabbit anti-GFP 1:1,000 (Molecular Probes A-11122)"
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,"rabbit anti-DH44 1:500 (Johnson et al., 2005)",0.85,Accept,Experimental Usage,rabbit anti-DH44 1:500
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,"guinea pig anti-PER 1:1,000 (I. Edery)",0.85,Accept,Experimental Usage,"guinea pig anti-PER 1:1,000"
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,mouse anti-PDF 1:500 (Developmental Studies Hybridoma Bank PDFC7; generated by J. Blau),0.95,Accept,Experimental Usage,mouse anti-PDF 1:500 (Developmental Studies Hybridoma Bank PDFC7)
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,"rabbit anti-SIFa 1:4,000 (gift from J. Veenstra)",0.85,Accept,Experimental Usage,"rabbit anti-SIFa 1:4,000"
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,Secondary antibodies were as follows: Alexa Fluor 488 goat anti-rabbit 1:500 (Molecular Probes A-11008),0.95,Accept,Experimental Usage,Alexa Fluor 488 goat anti-rabbit 1:500 (Molecular Probes A-11008)
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,fluorescein isothiocyanate (FITC) anti-guinea pig 1:500 (Jackson Laboratory 106-095-003),0.95,Accept,Experimental Usage,FITC anti-guinea pig 1:500 (Jackson Laboratory 106-095-003)
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,Cy5 donkey anti-mouse 1:400 (Jackson Laboratory 715-175-151),0.95,Accept,Experimental Usage,Cy5 donkey anti-mouse 1:400 (Jackson Laboratory 715-175-151)
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,Alexa Fluor 633 goat anti-rabbit (Molecular Probes A-21070),0.95,Accept,Experimental Usage,Alexa Fluor 633 goat anti-rabbit (Molecular Probes A-21070)
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,Loss of neurofibromin expression was confirmed by western blotting (Santa Cruz sc-67),0.9,Accept,Experimental Usage,Santa Cruz sc-67
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,"Adjacent sections were subjected to double immunofluorescence with anti-lacZ (rabbit, 1:200, 5′ and 3′) and anti-NeuN",0.85,Accept,Experimental Usage,"anti-lacZ antibody (rabbit, 1:200, 5′ and 3′)"
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,"double immunofluorescence with anti-lacZ (rabbit, 1:200, 5′ and 3′) and anti-NeuN (mouse, 1:200, Chemicon)",0.9,Accept,Experimental Usage,"anti-NeuN antibody (mouse, 1:200, Chemicon)"
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,"anti-lacZ and anti-GFAP (mouse, 1:100, Pharmingen)",0.9,Accept,Experimental Usage,"anti-GFAP antibody (mouse, 1:100, Pharmingen)"
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,BrdU immunohistochemistry was performed as described previously. The dilution of BrdU antibody was 1:50 (Becton Dickinson),0.9,Accept,Experimental Usage,"BrdU antibody (1:50, Becton Dickinson)"
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,"The dilution of primary antibodies used in this study were: GFAP (rabbit, 1:2000, DAKO)",0.9,Accept,Experimental Usage,"GFAP antibody (rabbit, 1:2000, DAKO)"
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,"nestin (mouse, 1:200, Chemicon)",0.9,Accept,Experimental Usage,"nestin antibody (mouse, 1:200, Chemicon)"
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,"BLBP (rabbit, 1:1000, a gift from N. Heintz)",0.85,Accept,Experimental Usage,"BLBP antibody (rabbit, 1:1000)"
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,"PAX2 (rabbit, 1:1000, a gift from G. Dressler)",0.85,Accept,Experimental Usage,"PAX2 antibody (rabbit, 1:1000)"
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,"P-erk (rabbit, 1:200, Cell Signaling)",0.9,Accept,Experimental Usage,"P-erk antibody (rabbit, 1:200, Cell Signaling)"
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,"Cre (mouse, 1:1000, BABCO)",0.9,Accept,Experimental Usage,"Cre antibody (mouse, 1:1000, BABCO)"
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,"Ki-67 (Rabbit, 1:1000, Novocastra Labs)",0.9,Accept,Experimental Usage,"Ki-67 antibody (Rabbit, 1:1000, Novocastra Labs)"
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,"Primary antibodies were rabbit polyclonal IgG anti-EGFR at 1:1,000 (Cell Signaling Technology, Danvers, MA)",0.9,Accept,Experimental Usage,rabbit polyclonal IgG anti-EGFR
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,rabbit immunoaffinity purified IgG anti-phospho-Tyr1068 of EGFR at 1:1000 (Cell Signaling Technology),0.9,Accept,Experimental Usage,rabbit immunoaffinity purified IgG anti-phospho-Tyr1068 of EGFR
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,"anti-MAP Kinase at 1:2,000 (Upstate Cell Signaling Solutions, Charlottesville, VA)",0.85,Accept,Experimental Usage,anti-MAP Kinase
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,"monoclonal IgG isotype anti-MAP Kinase activated, clone MAPK-YT at 1:2,000 (Sigma-Aldrich, St. Louis, MO)",0.9,Accept,Experimental Usage,"monoclonal IgG anti-MAP Kinase activated, clone MAPK-YT"
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,"mouse monoclonal anti-ErbB2 (LabVision, Freemont, CA) at 1:1000",0.85,Accept,Experimental Usage,mouse monoclonal anti-ErbB2
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,rabbit monoclonal and polyclonal anti-pTyr1221/1222 of ErbB2 (Cell Signaling Technology) at 1:500,0.9,Accept,Experimental Usage,rabbit monoclonal and polyclonal anti-pTyr1221/1222 of ErbB2
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,"mouse monoclonal anti-Cyclin D1 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:1000",0.85,Accept,Experimental Usage,mouse monoclonal anti-Cyclin D1
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,"mouse monoclonal IgG anti-β-tubulin ""E7"" at 1:2,000 (developed by Michael Klymkowsky and obtained from the Developmental Studies Hybridoma Bank)",0.9,Accept,Experimental Usage,mouse monoclonal IgG anti-β-tubulin E7
PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,membranes were probed with the following antibodies: phospho-p42/44 (pERK1/2) #9102 Cell Signaling (diluted 1:1000),0.95,Accept,Experimental Usage,phospho-p42/44 (pERK1/2) #9102 Cell Signaling
PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,p44 (ERK1) #4372 Cell Signaling (diluted 1:1000),0.95,Accept,Experimental Usage,p44 (ERK1) #4372 Cell Signaling
PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,"the single cell suspension was admixed with anti CD117, CD31, or Col1A and FcεRI antibodies.",0.8,Accept,Experimental Usage,anti CD117 antibody
PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,"the single cell suspension was admixed with anti CD117, CD31, or Col1A and FcεRI antibodies.",0.8,Accept,Experimental Usage,anti CD31 antibody
PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,"the single cell suspension was admixed with anti CD117, CD31, or Col1A and FcεRI antibodies.",0.8,Accept,Experimental Usage,anti Col1A antibody
PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,"the single cell suspension was admixed with anti CD117, CD31, or Col1A and FcεRI antibodies.",0.8,Accept,Experimental Usage,anti FcεRI antibody
